adult
lung
line
dynam
airway
epithelium
integr
epithelium
essenti
mainten
normal
lung
function
preserv
homeostasi
normal
function
follow
injuri
caus
variou
environment
insult
inhal
pollut
inflammatori
respons
varieti
stem
cell
respiratori
epithelium
would
turnov
steadi
state
lung
injuri
incur
prolifer
stemprogenitor
cell
differenti
form
cell
type
furthermor
crosstalk
lung
stem
cell
lsc
microenvironment
stem
cell
nich
crucial
mainten
balanc
stem
cell
differenti
deriv
tissu
homeostasi
defect
interact
may
lead
lung
damag
diseas
diseas
lung
cancer
chronic
obstruct
pulmonari
diseas
sever
slowli
progress
disabl
disord
associ
acceler
declin
lung
function
among
common
caus
death
world
research
lsc
signific
implic
understand
airway
epithelium
develop
function
health
diseas
may
provid
basi
futur
treatment
stem
cell
defin
unspeci
cell
capabl
selfrenew
differenti
divers
tissueor
organspecif
cell
stem
cell
also
essenti
embryon
develop
organogenesi
addit
normal
tissu
turnov
injuri
stem
cell
essenti
mainten
homeostasi
repair
adult
tissu
stem
cell
normal
quiescent
prolifer
infrequ
undergo
asymmetr
cell
divis
respons
injuri
stem
cell
prolifer
rapidli
give
rise
differenti
cell
cellbas
regen
medicin
open
new
way
therapeut
strategi
protect
repair
damag
tissu
therefor
abil
monitor
viabil
distribut
differenti
transplant
stem
cell
vivo
prerequisit
better
understand
role
stem
cell
play
therapeut
process
success
develop
cellbas
therapi
essenti
facilit
improv
number
stem
cell
engraft
target
area
monitor
traffick
label
stem
cell
molecular
cellular
imag
celllabel
strategi
current
perform
use
probe
incorpor
cell
transfect
report
gene
genom
nanotechnolog
provid
function
element
nanoscal
level
enabl
technolog
great
potenti
applic
cellbas
therapi
tradit
fate
transplant
stem
cell
gener
assess
direct
label
vitro
fluoresc
dye
radionuclid
eg
indium
oxin
thymidin
base
analog
eg
brdu
indirect
label
transfect
gene
fluoresc
protein
eg
gfp
report
protein
eg
luciferas
howev
sever
limit
exist
dilut
exclus
imag
probe
label
cell
insert
mutagenesi
transfect
cell
chang
cell
phenotyp
function
compound
issu
tissu
autofluoresc
comparison
tradit
fluoresc
probe
fluoresc
protein
smallmolecul
dye
nanoparticlebas
probe
advantag
term
photost
minim
alter
cell
phenotyp
function
howev
ideal
imag
technolog
stem
cell
track
sever
uniqu
featur
biocompat
nontox
exogen
contrast
agent
lack
genet
modif
perturb
stem
cell
resolut
singlecel
detect
appropri
anatom
locat
abil
quantif
minim
transfer
contrast
agent
cell
origin
label
noninvas
imag
live
subject
long
term
requir
inject
contrast
modal
fulfil
condit
requir
use
highli
sensit
imag
modal
well
employ
highli
stabl
biolog
photophys
imag
probe
allow
track
transplant
cell
vivo
extend
period
time
current
mani
nanomateri
quantum
dot
qd
silica
nanoparticl
polym
nanoparticl
use
fluoresc
imag
nobl
metal
nanoparticl
gold
particl
use
photoacoust
imag
superparamagnet
iron
oxid
particl
suitabl
magnet
reson
imag
use
label
track
stem
cell
vitro
vivo
comparison
modal
magnet
reson
imag
photoacoust
imag
positron
emiss
tomographi
comput
tomographi
optic
imag
possess
distinct
advantag
low
cost
easi
access
high
spatial
tempor
sensit
larg
vitro
vivo
throughput
greater
potenti
clinic
translat
exampl
qd
popular
fluoresc
platform
use
singleor
multiphoton
imag
techniqu
although
qd
adopt
highli
regard
fluoresc
imag
medium
applic
hamper
potenti
toxic
eg
cdse
qd
trap
endosomeslysosom
endocytosi
facil
degrad
eg
declin
fluoresc
ph
decreas
inde
exist
heavi
metal
qd
cadmium
wellestablish
human
toxic
carcinogen
pose
potenti
danger
especi
futur
medic
applic
use
nanomateri
biomed
applic
increas
environment
pollut
toxic
address
develop
nontox
biocompat
nanomateri
becom
import
issu
fluoresc
nanodiamond
fnd
new
member
nanocarbon
famili
recent
emerg
promis
nanotechnolog
imag
probe
biomed
applic
fnd
combin
advantag
qd
small
size
high
photost
bright
multicolor
fluoresc
biocompat
nontox
rich
surfac
chemistri
potenti
revolution
imag
applic
nanodiamond
compris
sp
hybrid
carbon
belong
carbonbas
nanomateri
famili
owe
low
chemic
reactiv
uniqu
physic
properti
nanodiamond
could
use
varieti
biolog
applic
natur
diamond
aggreg
nitrogen
defect
type
ia
diamond
synthet
diamond
manufactur
hightemperatur
highpressur
condit
mainli
embellish
singlesubstitut
nitrogen
center
type
ib
diamond
irradi
damag
type
ib
diamond
nanocrystallit
gener
intrins
defect
vacanc
diamond
structur
thermal
anneal
vacanc
move
toward
nitrogen
center
get
trap
within
form
nitrogenvac
nv
color
defect
center
center
lead
use
fluoresc
properti
excit
greenyellow
light
nm
fluorophor
eg
neg
charg
nv
center
nv
built
fnd
emit
stabl
far
emiss
nm
fluoresc
lifetim
greater
ns
addit
photoexcit
kwcm
power
densiti
light
min
photobleach
occur
fnd
contrast
condit
fluoresc
alexa
fluor
dye
photobleach
fade
complet
furthermor
fluoresc
blink
detect
within
time
resolut
ms
overal
extrem
photost
nv
defect
center
provid
great
advantag
fnd
emerg
excel
candid
longterm
cellular
imag
track
one
import
issu
concern
biomed
applic
autofluoresc
cell
tissu
fluoresc
endogen
compon
live
cell
tissu
fixativeinduc
fluoresc
commonli
refer
collect
autofluoresc
major
sourc
fluoresc
background
imag
experi
involv
biolog
sampl
major
cell
autofluoresc
origin
mitochondria
lysosom
togeth
aromat
amino
acid
lipopig
import
endogen
fluorophor
pyridin
nadph
flavin
coenzym
tissu
extracellular
matrix
often
contribut
autofluoresc
emiss
cellular
compon
collagen
elastin
among
endogen
fluorophor
rel
high
quantum
yield
absorpt
emiss
wave
cellular
endogen
fluorophor
rang
nm
overlap
organ
fluorophor
use
cellular
imag
far
fluoresc
emiss
fnd
peak
nm
well
separ
cellular
autofluoresc
region
biolog
specimen
anoth
import
paramet
could
util
improv
imag
contrast
fluoresc
probe
within
biolog
environ
issu
fluoresc
lifetim
fluoresc
lifetim
defin
time
fluorophor
remain
excit
state
return
ground
state
averag
fluoresc
lifetim
fnd
ns
consider
longer
typic
tissu
autofluoresc
common
fluoresc
imag
dye
ns
fluoresc
lifetim
imag
microscopi
flim
variou
nanosecond
timeg
techniqu
possibl
separ
fnd
emiss
strong
autofluoresc
background
host
tissu
nanotechnolog
great
potenti
enhanc
stem
cell
research
stem
cell
therapi
fnd
size
rang
nm
produc
ion
irradi
thermal
anneal
type
ib
diamond
powder
follow
air
oxid
purif
strong
oxid
acid
mention
fnd
novel
imag
probe
chemic
robust
fluoresc
stabl
also
biolog
inert
nontox
therefor
fnd
might
altern
longterm
label
stem
cell
past
year
sever
biocompat
cytotox
studi
conduct
examin
cell
viabil
oxid
stress
dna
damag
physiolog
process
vivo
label
cell
fnd
shown
fnd
could
use
mani
cell
line
without
obviou
cytotox
kidney
hek
lung
neuron
cervic
hela
cell
intern
fnd
affect
cell
viabil
cell
divis
assess
monitor
mitochondri
function
luminesc
atp
product
timelaps
imag
flow
cytometr
analysi
observ
number
fnd
nanoparticl
divid
nearli
equal
daughter
cell
cell
divis
fluoresc
intens
cell
decreas
exponenti
time
due
cell
prolifer
moreov
fndlabel
preadipocyt
osteoprogenitor
cell
cytotox
detriment
effect
prolifer
differenti
potenti
cell
flow
cytometri
transmiss
electron
microscop
use
seri
metabol
cytoskelet
inhibitor
found
mechan
fnd
uptak
cell
facilit
via
energydepend
clathrinmedi
endocytosi
addit
signific
exocytosi
fnd
found
cell
prolifer
besid
cellular
studi
histopatholog
examin
conduct
evalu
toxic
nanodiamond
vivo
intratrach
administ
nanodiamond
caus
pulmonari
toxic
amount
nanodiamond
alveolar
cell
decreas
time
macrophag
burden
nanodiamond
clearli
observ
bronchia
approxim
month
exposur
moreov
intraderm
subcutan
intraperiton
inject
nanodiamond
induc
inflammatori
reaction
system
toxic
mice
rat
microinject
wildtyp
caenorhabd
elegan
fnd
dispers
gonad
deliv
embryo
eventu
hatch
larva
next
gener
recent
simpson
et
al
also
demonstr
microinject
fnd
effect
nanoscal
fluoresc
probe
determin
intracellular
dynam
develop
drosophila
embryo
overal
fnd
photost
biocompat
nontox
potenti
use
label
imag
track
cellular
development
process
vitro
vivo
recent
work
also
demonstr
fnd
label
impair
biolog
function
lsc
adult
lung
complex
organ
consist
least
differ
cell
lineag
develop
sequenti
earli
epitheli
tube
branch
late
septat
termin
air
sac
base
anatom
function
featur
lung
divid
three
epitheli
domain
distinct
composit
epitheli
cell
type
proxim
cartilagin
airway
trachea
bronchi
distal
bronchiol
bronchiol
termin
bronchiol
respiratori
bronchiol
gasexchang
airspac
alveoli
human
mice
trachea
bronchi
line
pseudostratifi
epithelium
contain
basal
ciliat
secretori
goblet
serou
club
cell
small
number
neuroendocrin
cell
addit
submucos
gland
compos
interconnect
network
serou
mucou
tubul
secret
liquid
hydrat
airway
surfac
support
mucociliari
transport
serv
fluid
matrix
numer
secret
macromolecul
includ
gelform
mucin
bronchiol
cuboid
epithelium
contain
secretori
club
cell
fewer
ciliat
cell
moreproxim
airway
region
note
neuroendocrin
cell
found
resid
individu
cluster
neuroepitheli
bodi
distal
airway
alveolar
epithelium
lead
termin
bronchiol
compos
two
epitheli
cell
type
alveolar
type
pneumocyt
aeci
alveolar
type
ii
pneumocyt
aecii
aeci
cell
essenti
ga
exchang
larg
flat
squamou
cell
cover
alveolar
surfac
rel
smaller
granular
roughli
cuboid
aecii
cell
produc
surfact
compon
critic
mainten
alveolar
integr
contribut
alveolar
surfac
shown
fig
variou
subpopul
cell
around
bronchoalveolar
duct
junction
badj
lsc
alveolar
sac
resid
endogen
lsc
found
abl
renew
prolifer
epitheli
cell
vivo
potenti
use
regen
therapi
repair
damag
lung
tissu
patient
pseudoglandular
stage
lung
develop
distal
tip
branch
tubul
appear
contain
undifferenti
multipot
tip
cell
selfrenew
contribut
descend
epitheli
cell
lineag
follow
postnat
growth
lung
epithelium
slowli
turn
per
day
normal
condit
regen
capac
substanti
activ
injuri
larg
surfac
area
numer
branch
fold
topographi
suggest
lung
tissu
may
sever
stem
progenitor
cell
type
differ
region
stem
cell
lung
respons
postnat
lung
growth
homeostasi
repair
injur
lung
contribut
differ
local
need
time
tissu
damag
exampl
trachea
main
stem
bronchi
subset
basal
cell
domin
epitheli
stem
cell
type
respons
homeostasi
injuri
repair
possess
capac
differ
basal
ciliat
goblet
granular
secretori
cell
vivo
sever
cellular
marker
includ
cytokeratin
cytokeratin
integrin
nerv
growth
factor
receptor
employ
identif
isol
basal
cell
hand
ga
exchang
alveolar
epithelium
subset
aecii
cell
recogn
precursor
aeci
cell
adult
lung
hthymidin
label
clonogen
assay
genet
lineag
trace
analysi
aecii
cell
abl
prolifer
restor
alveolar
epithelium
give
rise
either
new
aecii
squamou
aeci
cell
follow
injuri
moreov
attempt
identifi
biomark
aecii
stem
cell
subset
prosurfact
protein
c
spc
integrin
cell
found
sporad
local
alveolar
epithelia
possess
capac
prolifer
differenti
spc
aecii
regener
lung
structur
date
least
subset
basal
secretori
mucou
cell
submucos
gland
proxim
airway
variant
club
cell
bronchiol
bronchoalveolar
stem
cell
basc
badj
termin
bronchiol
fig
subset
aecii
cell
alveolar
space
suggest
regionspecif
epitheli
stemprogenitor
cell
adult
lung
mice
human
distal
airway
bronchiolar
epithelium
quiescent
injuri
follow
naphthalenemedi
club
cell
ablat
small
number
naphthaleneresist
club
cell
term
variant
club
cell
surviv
regener
differenti
distal
bronchiolar
cell
type
variant
club
cell
express
club
cell
secretori
protein
ccsp
ccsp
locat
within
neuroepitheli
bodi
badj
kim
et
al
also
identifi
subpopul
club
cell
coexpress
ccsp
spc
refer
basc
anoth
naphthaleneresist
progenitor
cell
popul
locat
badj
use
naphthaleneor
bleomycininduc
murin
lung
injuri
model
demonstr
cell
possess
capac
selfrenew
injuri
repair
vivo
abil
differenti
club
cell
alveolar
epitheli
cell
addit
basc
lab
previous
report
serum
freeselect
cultur
procedur
sustain
preferenti
growth
lung
coloni
support
pulmonari
mesenchym
cell
surround
cell
popul
also
resid
termin
bronchiolar
region
neonat
lung
introduc
put
neonat
lung
stemprogenitor
cell
capabl
cultur
vitro
week
induc
differenti
aecii
aeci
cell
interestingli
cell
suscept
infect
sever
acut
respiratori
syndrom
sar
viru
rais
possibl
lsc
may
specif
diseas
target
therefor
studi
suggest
lsc
could
target
environment
agent
includ
pneumotrop
pathogen
lsc
play
protect
role
epitheli
repair
tissu
homeostasi
direct
isol
cell
import
challeng
one
hand
conceiv
differ
popul
stem
cell
could
isol
differ
region
lung
tissu
sever
comprehens
analys
transcriptom
proteom
analys
use
elucid
gene
protein
express
profil
determin
novel
molecular
marker
howev
specif
surfac
marker
cell
valuabl
isol
stem
cell
mani
commonli
use
stem
cell
marker
often
adopt
phenotyp
characterist
cell
type
hematopoiet
cell
lineag
limit
insight
specif
stem
cell
studi
although
sever
put
marker
stem
cell
subpopul
lung
tissu
studi
great
detail
basc
badj
basal
cell
proxim
airway
specif
marker
unambigu
identif
isol
lsc
defin
yet
specif
surfac
marker
thu
need
prepar
homogen
popul
lsc
cell
surfac
compon
glycosyl
glycom
analysi
use
probe
stem
cell
cancer
cell
surfac
systemat
search
novel
glycoprotein
glycolipid
recent
took
anoth
step
forward
develop
new
prospect
isol
method
obtain
lsc
glycoproteom
analysi
fig
briefli
alkynyl
sugar
deriv
incorpor
glycoprotein
tag
biotin
azid
use
click
chemistri
permit
enrich
proteom
via
affin
captur
immobil
avidin
follow
tryptic
digest
bead
protein
id
identifi
liquid
chromatographytandem
mass
spectrometri
lcmsm
fig
analysi
identifi
total
protein
uniqu
express
lscenrich
cell
popul
examin
uniprot
databas
indic
glycoprotein
plasma
membran
protein
eg
surfac
marker
accord
realtim
polymeras
chain
reaction
pcr
immunofluoresc
stain
found
bone
marrow
stromal
cell
antigen
specif
express
cell
surfac
lsc
coloni
type
differenti
lung
cell
fig
addit
also
shown
cell
lung
section
locat
termin
bronchiol
badj
upon
immunohistochem
analysi
fig
consist
brdu
retain
cell
previou
studi
therefor
use
one
new
surfac
marker
ensu
experi
prospect
isol
lsc
fluorescenceactiv
cell
sort
fac
stain
two
specif
cell
surfac
marker
propidium
iodid
antibodi
achiev
isol
subpopul
cell
highli
enrich
lsc
neonat
lung
tissu
cell
capabl
selfrenew
could
also
maintain
coloni
morpholog
serial
passag
fig
furthermor
isol
cell
could
cryopreserv
thaw
without
signific
loss
abil
cell
renew
extens
expans
similar
origin
isol
lsc
cobblestonelik
cell
morpholog
maintain
expans
fulli
character
sort
cell
immunofluoresc
analysi
first
perform
time
isol
isol
cell
express
club
cell
marker
ccsp
epitheli
cell
marker
pneumocyt
marker
day
cultur
growth
medium
chang
express
marker
fig
isol
character
lung
stem
cell
addit
abil
selfrenew
expans
also
examin
whether
sort
expand
cell
possess
capac
stem
cell
differenti
day
incub
induct
medium
cell
shape
becam
flatten
size
becam
larger
aecii
cell
marker
spc
express
detect
cytoplasm
close
perinuclear
region
indic
cell
differenti
aecii
cell
fig
extens
incub
day
led
flatten
enlarg
cell
approxim
fivefold
greater
origin
undifferenti
cell
morpholog
chang
accompani
decreas
spc
express
increas
workflow
glycoproteom
analysi
b
mrna
express
associ
lscenrich
cell
aecii
stromal
cell
lung
tissu
immunohistochem
stain
black
brown
web
version
lung
tissu
section
neonat
mice
c
phase
contrast
imag
lsc
coloni
deriv
sort
cell
day
immunofluoresc
stain
sort
cell
anticytokeratin
anticcsp
antibodi
examin
induc
differenti
cell
aecii
marker
prosurfact
protein
c
spc
incub
medium
day
aeci
marker
aquaporin
incub
anoth
day
lcmsm
liquid
chromatographytandem
mass
spectrometri
fig
aeci
cell
marker
aquaporin
express
indic
prospect
isol
cell
potenti
differenti
aecii
cell
aeci
cell
sequenti
manner
fig
lsc
label
fnd
show
fndlabel
cell
display
one
use
featur
flow
cytometr
analysi
addit
far
fluoresc
data
collect
side
scatter
channel
ssc
also
provid
use
inform
fnd
uptak
due
fact
diamond
highest
refract
index
transpar
miner
diamond
nanoparticl
scatter
light
strongli
visibl
region
thu
produc
strong
ssc
signal
properli
gate
bivari
plot
ssc
versu
far
quadrant
two
distinct
separ
popul
fndlabel
unlabel
cell
could
detect
two
channel
doubleposit
cell
popul
denot
ssc
far
subsequ
identifi
fndlabel
cell
without
addit
stain
furthermor
analysi
reveal
control
fndlabel
lsc
abl
undergo
morpholog
alter
express
spc
day
induct
lsc
form
aecii
cell
impli
endocyt
fnd
chang
appar
biolog
function
stem
cell
fig
furthermor
interfer
fnd
detect
differenti
aecii
aeci
suggest
fnd
impair
biolog
function
lsc
fig
addit
track
prolifer
fndlabel
lsc
continu
week
flow
cytometri
found
lsc
label
fnd
viabl
continu
prolifer
least
week
approxim
seven
divis
suggest
extent
fnd
exocytosi
low
track
home
capac
isol
expand
lsc
vivo
fndlabel
cell
inject
tail
vein
adult
mice
addit
lung
tissu
kidney
liver
spleen
also
harvest
examin
day
intraven
iv
inject
fndlabel
cell
mice
lung
tissu
section
mice
infus
fndlabel
cell
prepar
fluoresc
imag
fig
meanwhil
verifi
fndlabel
consequ
fnd
engulf
macrophag
lung
section
stain
macrophagespecif
antibodi
follow
hematoxylin
counterstain
fig
howev
search
fnd
immunohistochem
stain
tissu
section
note
imag
overwhelm
tissu
autofluoresc
also
fluoresc
deriv
photoexcit
hematoxylin
counterstain
thu
prevent
detect
fnd
signal
fig
use
flim
howev
background
fluoresc
fnd
signal
readili
separ
fluoresc
lifetim
fnd
substanti
longer
endogen
autofluoresc
tissu
section
typic
ns
fig
gate
time
ns
locat
fnd
lung
vivo
track
fndlabel
lung
stem
cell
tissu
could
clearli
identifi
fig
furthermor
overlap
brightfield
tgf
imag
indic
fnd
coloc
macrophag
lung
tissu
lead
conclus
fndlabel
lsc
alveolar
sac
region
engulf
alveolar
macrophag
flow
cytometr
identif
ssc
far
cell
confirm
inject
cell
preferenti
resid
lung
tissu
also
found
day
approxim
total
popul
viabl
cell
lung
appear
fndlabel
lsc
fraction
ssc
far
cell
howev
decreas
respect
day
inject
verifi
whether
ssc
far
cell
sort
fac
truli
fndlabel
cell
inject
lung
tissu
section
stain
hematoxylin
eosin
h
e
morpholog
analysi
timeg
techniqu
similarli
appli
imag
lung
tissu
prepar
day
fnd
fluoresc
red
spot
could
readili
distinguish
background
fluoresc
time
gate
ns
fig
confirm
fnd
made
prolong
excit
lead
signific
decreas
fluoresc
intens
consist
characterist
fnd
fluoresc
merg
imag
brightfield
h
e
stain
tgf
found
fndlabel
lsc
trap
interalveolar
space
fig
mani
resid
close
label
prospect
isol
lsc
fnd
elimin
abil
stem
cell
prolifer
differenti
type
type
ii
pneumocyt
vitro
fnd
label
combin
fluorescenceactiv
cell
sort
fac
fluoresc
lifetim
imag
microscopi
flim
timeg
fluoresc
tgf
imag
could
identifi
lsc
transplant
vivo
allow
track
engraft
regen
capabl
singlecel
resolut
termin
bronchiol
badj
addit
fndlabel
cell
retain
region
lung
least
day
inject
demonstr
potenti
lsc
home
engraft
track
cell
vivo
use
mice
pretreat
naphthalen
naphthalen
caus
lung
injuri
mainli
distal
bronchiolar
club
cell
without
significantli
deplet
alveolar
epitheli
cell
mous
shown
fig
mice
receiv
either
normal
salin
mgkg
naphthalen
intraperiton
day
later
fndlabel
lsc
inject
lunginjur
control
mice
via
iv
administr
mice
sacrif
differ
time
point
organ
collect
search
inject
lsc
fluoresc
microscopi
fig
mention
highautofluoresc
background
prevent
clear
identif
cell
lung
thank
distinct
fluoresc
lifetim
nv
center
undesir
effect
could
larg
remov
flim
tgf
fig
show
flim
imag
lung
tissu
collect
day
inject
cell
clearli
discern
even
cell
stain
h
e
aid
histolog
examin
fig
arrow
first
fndlabel
lsc
preferenti
resid
termin
bronchiol
lung
day
iv
administr
confirm
tgf
imag
tissu
section
naphthaleneinjur
mice
singlecel
resolut
fig
addit
damag
lung
cell
rapidli
recov
transplant
fndlabel
lsc
mice
shown
increas
pancytokeratin
panck
ccsp
epitheli
cell
fig
import
implic
present
studi
prospect
isol
lsc
potenti
use
new
cell
sourc
stem
cellbas
therapi
regen
medicin
experi
injuri
repair
bronchiolar
epithelium
assess
immunostain
club
cell
specif
marker
ccsp
day
injuri
inject
found
day
bronchiolar
epithelium
lunginjur
mice
spars
surround
cell
express
ccsp
control
salinetr
fnd
lsctreat
mous
group
day
although
progress
club
cell
regener
occur
salinetr
mice
bronchiolar
epithelium
fnd
lsctreat
mice
display
significantli
enhanc
repopul
club
cell
ccsp
stain
fig
almost
complet
restor
club
cell
suggest
transplant
fndlabel
lsc
involv
lung
repair
homeostasi
suggest
addit
support
flow
cytometr
identif
ssc
far
cell
reveal
day
day
lsc
inject
injuri
mice
approxim
total
popul
viabl
cell
associ
fndlabel
lsc
lung
word
percentag
fndlabel
lsc
show
pronounc
decreas
entir
week
naphthalen
treatment
fig
situat
total
differ
uninjur
mice
discrep
result
experi
uninjur
injur
mice
demonstr
home
capac
fndlabel
lsc
last
lung
tissu
section
prepar
mice
day
day
inject
fndlabel
lsc
stain
h
e
morpholog
analysi
tgf
imag
show
fndlabel
lsc
preferenti
local
termin
bronchiol
lunginjur
mice
moreov
use
flim
imag
immunohistochemistri
epitheli
marker
panck
clare
cell
marker
ccsp
found
fndlabel
cell
locat
epithelium
region
fig
increas
fndlabel
lsc
popul
bronchiol
togeth
fluoresc
imag
reflect
lsc
preferenti
home
termin
bronchiol
badj
lunginjur
mice
known
lung
epithelium
slowli
turn
normal
condit
regen
capac
could
activ
injuri
similarli
bone
marrow
transplant
also
requir
specif
myeloabl
condit
recipi
creat
space
accommod
hematopoiet
stem
cell
donor
lung
injuri
experi
epithelium
restor
rapidli
transplant
fndlabel
cell
injur
model
furthermor
provid
semiquantit
estim
stem
cellhom
effici
calcul
proport
fndlabel
cell
home
lung
p
h
follow
equat
n
v
equal
percent
fndlabel
cell
determin
flow
cytometri
p
equal
total
number
cell
lung
n
equal
number
cell
actual
transplant
fig
experi
number
fndlabel
cell
transplant
mice
experi
total
number
cell
isol
mous
lung
tissu
approxim
cell
viabl
cell
pi
moreov
ssc
far
cell
ie
fndlabel
cell
pi
gate
day
declin
day
normal
uninjur
mice
thu
proport
transplant
cell
home
lung
p
h
could
estim
similar
calcul
result
decreas
proport
transplant
cell
remain
lung
becom
ie
therefor
normal
uninjur
mice
signific
decreas
valu
transplant
cell
lung
day
day
fig
word
transplant
cell
initi
entrap
lung
disappear
lung
day
sharp
contrast
similar
calcul
lung
injuri
model
reveal
proport
transplant
fndlabel
cell
home
lung
show
signific
decreas
day
ie
day
day
fig
result
seem
impli
lodgment
transplant
fndlabel
cell
injur
model
indic
proactiv
home
nonspecif
passiv
entrap
use
lsc
stem
cell
therapi
reli
home
capac
longterm
engraft
cell
appropri
nich
lung
tissu
although
mechan
prospect
isol
lsc
reach
lung
tissu
home
badj
upon
iv
transplant
yet
fulli
understood
specul
play
crucial
role
process
previou
studi
found
marker
essenti
stem
cell
home
recruit
circul
epitheli
progenitor
cell
specif
site
airway
injuri
studi
inde
express
cell
coloni
cell
serum
freeselect
cultur
suggest
marker
may
also
facilit
home
cell
regener
epithelium
transplant
tgf
imag
tissu
section
naphthaleneinjur
mice
indic
fndlabel
lsc
preferenti
resid
termin
bronchiol
lung
iv
inject
result
demonstr
feasibl
find
rare
stem
cell
vivo
innov
fndflim
imag
technolog
also
engraft
capac
regen
potenti
prospect
isol
lsc
uninjur
mice
signific
decreas
transplant
cell
detect
lung
day
low
level
day
seem
transplant
cell
initi
entrap
lung
disappear
lung
day
contrast
similar
calcul
lung
injuri
model
reveal
proport
transplant
fndlabel
cell
home
lung
show
signific
chang
day
result
thu
impli
lodgment
transplant
fndlabel
cell
injur
model
indic
proactiv
home
nonspecif
passiv
entrap
notabl
fact
lung
repair
injuri
mice
becam
significantli
enhanc
inject
lsc
impli
feasibl
cell
therapi
regen
medicin
therefor
present
nanoparticlebas
platform
combin
fnd
label
fac
flim
tgf
imag
immunostain
assess
tissuespecif
engraft
regen
potenti
stem
cell
transplant
vivo
moreov
approach
offer
new
insight
compon
limit
accept
transplant
stem
cell
vivo
well
mechan
regener
within
host
nanotechnolog
hold
great
potenti
monitor
home
differ
kind
stem
cell
preclin
experiment
thu
enabl
technolog
applic
stem
cell
research
regen
medicin
human
immunodefici
viru
hiv
caus
agent
human
acquir
immunodefici
syndrom
aid
epicent
global
epidem
affect
million
peopl
constitut
major
problem
especi
develop
countri
subsaharan
africa
preval
transmiss
rate
higher
access
treatment
prevent
still
limit
current
treatment
reli
use
multipl
antiretrovir
drug
inhibit
differ
step
viru
infect
cycl
combin
antiretrovir
therapi
cart
abl
improv
health
patient
particularli
start
earli
infect
lifelong
treatment
requir
therapeut
regimen
often
hard
implement
especi
consid
poor
patient
adher
side
effect
feasibl
cure
hiv
infect
unlik
avail
near
futur
control
epidem
reli
larg
prevent
intervent
among
recent
proven
effect
oral
preexposur
prophylaxi
prep
alreadi
approv
sever
countri
unit
state
canada
franceand
topic
microbicid
also
refer
topic
prep
may
particularli
promis
fulfil
unmet
need
avert
new
infect
despit
excit
result
oral
prep
men
sex
men
protect
among
heterosexu
women
shown
inconsist
issu
relat
poor
adher
biolog
differ
rout
transmiss
vagin
vs
rectal
may
involv
also
oral
prep
limit
onset
system
advers
effect
also
typic
seen
cart
topic
microbicid
struggl
throughout
roughli
last
quarter
centuri
achiev
proof
concept
human
clinic
trial
recent
success
may
boost
invest
develop
market
introduct
dapivirin
vagin
ring
forefront
product
like
rise
come
year
rectal
microbicid
also
develop
advanc
slower
recogn
drug
formul
deliveri
play
import
role
develop
topic
microbicid
mani
strategi
involv
use
convent
dosag
form
novel
deliveri
system
propos
test
variou
antihiv
compound
subchapt
describ
recent
develop
field
nanotechnologybas
carrier
system
deliveri
antiretrovir
compound
purpos
topic
prevent
sexual
hiv
transmiss
unaid
estim
around
million
peopl
worldwid
live
hiv
end
million
becam
newli
infect
singl
year
type
viru
account
case
easier
transmit
virul
type
hiv
transmiss
may
occur
sexual
blood
vertic
mothertochild
contact
although
major
infect
burden
aris
unprotect
sex
cervicovagin
rectal
mucosa
viru
exploit
sever
pathway
reach
main
target
cell
name
cell
hiv
also
infect
cell
macrophag
dendrit
cell
dc
fig
present
schemat
represent
main
mechan
possibl
pathway
behind
transmiss
cervicovagin
mucosa
lack
cure
hivaid
make
prevent
essenti
approach
fight
epidem
effect
vaccin
still
elus
sever
modal
current
avail
proven
least
partial
effect
tabl
howev
largescal
implement
prevent
measur
shown
huge
challeng
requir
invest
name
novel
strategi
avoid
sexual
transmiss
particular
urgent
need
alongsid
oral
prep
antiretrovir
drug
possibl
deliv
antihiv
compound
vagin
rectal
rout
attract
consider
attent
microbicid
defin
product
vagin
andor
rectal
deliveri
block
earli
viral
transmiss
event
mucos
level
microbicid
consid
particularli
import
may
repres
mean
women
risk
protect
without
need
consent
cooper
even
knowledg
male
partner
even
unlik
confer
full
protect
microbicid
may
still
import
role
avert
hiv
infect
combin
prevent
strategi
contrari
oral
prep
antiretrovir
drug
intend
concentr
mucosa
reach
system
circul
signific
level
thu
contribut
amelior
advers
effect
develop
product
intend
circumv
anogenit
mucos
transmiss
viru
receiv
much
need
boost
recent
releas
result
two
phase
clinic
trial
test
dapivirin
vagin
ring
still
tent
microbicid
product
shown
mildli
effect
reduc
transmiss
men
women
compar
placebo
ring
result
line
tenofovir
gel
test
caprisa
phase
clinic
trial
first
studi
show
protect
vagin
microbicid
combin
partial
success
trial
suggest
addit
work
develop
novel
solut
may
use
potenti
improv
efficaci
microbicid
rectal
microbicid
develop
still
earlier
stage
human
efficaci
studi
conduct
yet
consid
issu
lesser
relev
microbicid
drug
formul
taken
essenti
place
develop
formul
effort
lead
stabl
safe
potenti
effect
product
also
accept
user
present
well
establish
relationship
pharmacokinet
pk
pharmacodynam
exist
sever
microbicid
drug
name
dapivirin
tenofovir
higher
local
concentr
relat
enhanc
protect
adequ
design
vagin
rectal
product
may
contribut
increas
sustain
drug
level
product
develop
far
reli
convent
dosag
form
particularli
gel
consid
practic
cheap
manufactur
limit
exist
potenti
poor
physicochem
microbiolog
stabil
alongsid
issu
concern
leakag
messi
upon
administr
moreov
use
gel
coitu
depend
product
requir
administ
immedi
andor
everi
sexual
intercours
effect
rais
issu
concern
adher
regard
one
challeng
topic
influenc
efficaci
microbicid
dosag
form
also
consid
name
tablet
capsul
suppositori
cream
solut
suspens
foam
advanc
develop
slow
presum
limit
advantag
exist
compar
gel
vagin
film
seen
interest
altern
dosag
form
gel
name
due
compact
size
increas
stabil
decreas
abil
caus
vagin
leakag
particular
film
contain
dapivirin
test
recent
phase
clinic
trial
result
suggest
safe
provid
potenti
protect
genit
drug
level
howev
film
suitabl
rectal
administr
alongsid
convent
dosag
form
limit
need
administ
everi
time
sexual
intercours
occur
vagin
ring
engin
deliv
differ
antiretrovir
drug
use
coitusindepend
microbicid
place
vagina
ring
releas
drug
sustain
fashion
sever
week
even
month
notwithstand
potenti
abbrevi
adher
issu
dapivirin
ring
provid
modest
protect
women
describ
subchapt
data
requir
fulli
understand
result
frequent
ring
remov
particularli
around
time
sexual
intercours
possibl
explan
anoth
import
aspect
need
stress
concern
specif
vagin
rectal
rout
mention
dosag
form
rout
specif
name
ring
film
apart
biolog
vagin
rectal
milieu
requir
consid
meet
requir
safeti
administr
distribut
overal
local
pk
descript
main
characterist
vagina
colorectum
beyond
scope
manuscript
detail
main
anatom
histolog
physiolog
featur
rout
particular
relev
develop
microbicid
found
previou
public
research
group
advanc
field
nanomedicin
tremend
last
decad
sever
nanotechnologybas
drug
product
alreadi
reach
market
worldwid
encourag
achiev
boost
interest
appli
nanotechnolog
healthcar
field
hiv
treatment
prevent
except
develop
nanomicrobicid
receiv
increas
interest
case
convent
drug
deliveri
approach
mostli
provid
protect
vagin
hiv
transmiss
microbicid
nanosystem
may
conveni
classifi
possess
inher
activ
either
interact
directli
hiv
block
virushost
cell
interact
act
carrier
antihiv
compound
first
case
dendrim
focu
extens
develop
particular
dendrim
formul
gel
vivagel
starpharma
abbotsford
victoria
australia
test
vagin
microbicid
fourthgener
dendrim
compris
polylysin
branch
attach
central
core
benzhydrylamin
amid
polylysin
termin
derivat
naphthalen
disulfon
group
respons
interact
particularli
viral
envelop
glycoprotein
play
crucial
role
infect
bind
receptor
one
coreceptor
present
host
cell
membran
vivagel
underw
seri
promis
clinic
trial
possibl
onset
safeti
issu
seem
halt
develop
microbicid
product
use
gel
formul
rectal
deliveri
also
explor
recent
variou
carbosilan
dendrim
propos
promis
altern
vitro
vivo
data
seem
attest
potenti
roughli
last
decad
research
nanotechnologybas
microbicid
mainli
focus
develop
nanocarri
promis
antihiv
compound
name
antiretrovir
drug
alreadi
test
clinic
trial
follow
releas
result
caprisa
trial
tenofovir
deriv
becam
immedi
candid
develop
drugload
nanosystem
differ
type
nanocarri
intend
vagin
deliveri
develop
includ
solid
lipid
nanoparticl
sln
chitosan
thiolat
chitosan
nanoparticl
np
phsensit
poli
lacticcoglycol
acid
plga
eudragit
np
hyaluronidasesensit
hyaluron
acid
np
nanofib
load
tenofovir
also
recent
propos
develop
vagin
microbicid
apart
tenofovir
wide
varieti
vagin
nanocarri
develop
antihiv
compound
name
pscrantesload
plga
np
dapivirineload
polycaprolacton
pcl
np
efavirenzraltegravirload
plga
np
efavirenzor
saquinavirload
plga
np
saquinavirload
plga
np
dapivirineload
plga
np
efavirenzload
cellulos
acet
phthalat
cap
np
efavirenzcurcuminload
lactoferrin
np
overal
advantag
featur
use
nanosystem
vagin
deliveri
activ
compound
may
includ
control
releas
enhanc
solubl
protect
labil
molecul
improv
distribut
throughout
mucosa
modul
mucoadhes
behavior
improv
interact
host
cell
eg
lead
higher
intracellular
drug
concentr
provid
target
drug
deliveri
hivsuscept
cell
enhanc
drug
penetrationaccumul
genit
tissu
one
issu
focu
intens
research
discuss
last
decad
relat
mucoadhes
behavior
nanosystem
regard
advantag
extens
interact
cervicovagin
mucu
consid
potenti
deleteri
decreas
transport
nanosystem
result
poor
abil
reach
epitheli
line
interact
cell
interest
differ
strategi
describ
decreas
mucoadhes
dens
surfac
modif
np
rel
shortchain
linear
poli
ethylen
oxid
peo
also
commonli
refer
poli
ethylen
glycol
preferenti
research
rectal
nanomicrobicid
nearli
nonexist
much
work
still
requir
advantag
point
earlier
vagin
administr
nanosystem
may
appli
exampl
data
anim
studi
human
clinic
trial
indic
np
may
interest
approach
improv
distribut
retent
throughout
colorectum
well
enhanc
transport
across
mucu
barrier
specif
studi
describ
regard
nanomicrobicid
exampl
data
vitro
ex
vivo
studi
cell
anim
colorect
tissu
support
dapivirineload
pcl
np
may
success
engin
safe
effect
consid
rectal
administr
anoth
studi
nanoconjug
proteas
inhibitor
amprenavir
peo
cell
penetr
peptid
found
particularli
use
enhanc
drug
uptak
colorect
tissu
administ
intrarect
mice
mention
earlier
substanti
effort
place
develop
vagin
nanocarri
system
compound
may
potenti
inhibit
transmiss
mucos
level
next
subsect
partial
reproduc
updat
recent
review
group
subject
describ
illustr
case
studi
microbicid
nanocarri
advanc
preclin
stage
develop
particular
focu
vivo
evalu
dapivirin
diarylpyrimidin
compound
one
lead
microbicid
drug
candid
current
evalu
two
phase
clinic
trial
vagin
ring
although
possess
potent
activ
dapivirin
present
problemat
featur
name
poor
solubl
aqueou
vehicl
limit
formul
approach
group
engag
year
develop
differ
polymer
np
carrier
altern
vagin
deliveri
dapivirin
np
extens
evalu
vitro
stabil
toxic
activ
interact
variou
cell
type
mucuslik
fluid
cell
monolayertissu
permeabl
drug
retent
exampl
pcl
np
shown
maintain
antivir
activ
dapivirin
upon
encapsul
fig
modul
toxic
differ
accord
select
particl
stabil
peomodifi
np
improv
toxic
profil
incorpor
sodium
lauryl
sulfat
sl
cetyltrimethylammonium
bromid
ctab
particl
composit
gener
chang
increas
cytotox
respect
pcl
np
shown
penetr
pig
vagin
rectal
mucosa
ex
vivo
fig
enhanc
dapivirin
accumul
tissu
particular
peomodifi
pclbase
nanoparticul
system
present
mean
hydrodynam
diamet
around
nm
emerg
optim
candid
deliveri
dapivirin
test
vivo
peopcl
np
first
evalu
mous
model
genit
distribut
vagin
instil
ph
phosphat
buffer
salin
pb
vehicl
fig
quantit
analysi
evidenc
rapid
remov
np
genit
tract
approxim
loss
min
h
postadministr
respect
even
signific
amount
particl
still
recov
vagin
tissu
nearli
min
h
respect
fast
particl
deplet
associ
use
pb
instead
solid
semisolid
vehicl
could
tackl
least
partial
leakag
vagina
notic
np
still
abl
penetr
vagin
mucosa
ten
micromet
deep
fig
thu
potenti
assur
drug
depot
within
tissu
local
pk
also
assess
h
postadministr
dapivirin
pb
either
associ
np
suspens
fig
result
show
np
abl
better
sustain
drug
level
vagin
lavag
vagin
tissu
partial
lower
half
uterin
horn
despit
overal
fast
decreas
dapivirin
amount
genit
tract
vagin
lavag
drug
level
seem
maintain
level
previous
found
protect
human
mous
model
h
anim
treat
np
h
case
dapivirin
suspens
furthermor
dapivirin
abl
reach
concentr
xaxi
express
dapivirin
virtual
dapivirin
case
np
drug
point
repres
mean
valu
bar
standard
deviat
n
asterisk
denot
signific
differ
p
compar
free
dapivirin
ctab
cetyltrimethylammonium
bromid
pcl
polycaprolacton
peo
poli
ethylen
oxid
sl
sodium
lauryl
sulfat
rectal
tissu
quantifi
amount
fig
like
due
extern
access
vagin
leakag
signific
find
potenti
protect
rectal
infect
deserv
investig
overal
local
pk
data
seem
promis
consid
develop
daili
coitusindepend
microbicid
product
still
anim
efficaci
studi
requir
truli
assess
obtain
pk
data
dapivirineload
peopcl
np
also
shown
safe
upon
daili
vagin
administr
day
assess
histolog
analysi
assay
inflammatori
chemokinecytokin
level
vagin
lavag
system
drug
exposur
low
case
rilpivirin
nonnucleosid
revers
transcriptas
inhibitor
chemic
class
dapivirin
current
use
aid
therapi
drug
also
develop
longact
npbase
inject
use
prep
recent
report
kovarova
et
al
propos
evalu
efficaci
nanotechnologybas
formul
rilpivirin
human
blt
mice
peomodifi
plga
np
mean
hydrodynam
diamet
nm
select
drug
carrier
incorpor
poloxamerbas
thermosensit
gel
undergo
solgel
transit
bodi
temperatur
drug
concentr
gel
approxim
ww
use
gel
adapt
previou
work
undertaken
one
author
research
group
allow
eas
administr
enhanc
vagin
retent
np
rilpivirin
anim
treat
intravagin
rilpivirineload
np
gel
h
viral
challeng
tcid
rhpa
fulli
protect
infect
protect
decreas
time
elaps
gel
administr
viral
challeng
extend
h
control
mice
infect
hiv
irrespect
time
administr
author
studi
claim
observ
protect
effect
link
format
layer
np
cover
cervicovagin
epithelium
partial
persist
h
postadministr
np
also
abl
penetr
tissu
till
vicin
hivsuscept
cell
although
pk
data
provid
result
suggest
signific
amount
drug
retain
vagina
least
h
addit
assess
real
valu
np
gel
formul
provid
protect
easi
control
contain
free
rilpivirin
includ
studi
tenofovir
disoproxil
fumar
tdf
prodrug
tenofovir
possess
higher
hydrophob
result
higher
tissu
permeabl
cell
uptak
compar
parent
molecul
thu
lead
enhanc
potenc
featur
alon
may
justifi
use
altern
tenofovir
obtain
potent
microbicid
recent
report
studi
destach
et
al
incorpor
tdf
plga
np
mean
hydrodynam
diamet
nm
use
sodium
deoxychol
ionpair
agent
addit
sodium
deoxychol
allow
enhanc
drug
associ
np
time
np
incorpor
poloxamerbas
thermosensit
gel
differ
tdf
concentr
facilit
vagin
administr
gel
administ
human
blt
mice
intravagin
challeng
anim
treat
placebo
thermosensit
gel
challeng
h
infect
convers
mice
fulli
protect
administ
differ
gel
contain
tdfload
np
challeng
viru
differ
time
point
posttreat
tdf
h
tdf
h
protect
observ
tdfload
np
gel
tdf
use
day
viral
challeng
result
appear
support
tdfload
np
thermosensit
gel
may
use
coitusindepend
effect
microbicid
howev
data
gel
contain
tdf
alon
ie
without
incorpor
np
provid
difficult
assess
real
valu
nanocarri
protect
viral
infect
also
use
gel
bear
differ
quantiti
tdf
differ
challeng
time
consid
lack
detail
pk
data
make
difficult
fulli
understand
valu
otherwis
interest
studi
despit
frequent
consid
vagin
drug
deliveri
featur
wellknown
technolog
versatil
stabil
biocompat
liposom
carrier
mostli
overlook
develop
nanomicrobicid
one
except
use
commerci
avail
novasom
novavax
gaithersburg
maryland
usa
igi
laboratori
buena
new
jersey
usa
vagin
deliveri
rant
truncat
fragment
regul
activ
normal
express
secret
rant
chemokin
present
high
specif
bind
novasom
nm
nonphospholipid
liposom
compris
monoest
peo
fatti
acid
cholesterol
free
fatti
acid
associ
rant
novasom
affect
nativ
activ
protein
data
initi
studi
kishcatalon
et
al
abl
indic
rant
liposom
complex
elicit
mild
sign
inflamm
administ
mice
singl
dose
rabbit
daili
administr
consecut
day
thu
consid
accept
vagin
use
efficaci
complex
vagin
transmiss
shiv
test
cynomolgu
macaqu
pretreat
min
anim
rantesliposom
complex
pb
viral
challeng
result
partial
yet
signific
protect
compar
anim
treat
pb
alon
rant
pb
solut
provid
signific
protect
use
concentr
nearli
time
use
complex
remark
blank
liposom
present
similar
protect
result
compar
carri
rant
possibl
explan
may
inher
antivir
activ
novasom
document
liposom
vesicl
case
abil
liposom
evenli
distribut
throughout
mucosa
seem
import
creat
protect
barrier
viral
transmiss
addit
studi
necessari
clarifi
issu
strategi
compris
mucos
posttranscript
gene
silenc
consid
promis
prevent
sexual
transmiss
hiv
rna
interfer
rnai
name
use
small
interfer
rna
sirna
may
constitut
rel
simpl
yet
challeng
approach
silenc
gene
code
import
molecul
involv
life
cycl
hiv
particularli
host
origin
despit
signific
advanc
made
field
issu
regard
intracellular
deliveri
molecular
stabil
offtarget
effect
oligonucleotid
may
impair
success
novel
formul
approach
requir
furthermor
specif
mucos
site
vagina
may
present
specif
addit
limit
topic
deliveri
labil
molecul
eg
sirna
role
nanotechnolog
aid
rnaibas
therapeut
well
recogn
applic
field
antihiv
microbicid
scarc
best
knowledg
report
eszterha
et
al
boyapal
et
al
constitut
studi
subject
first
group
research
use
commerci
cation
polym
transfect
agent
interferin
polyplustransfect
produc
nm
polyplex
sirna
obtain
nanosystem
abl
partial
suppress
express
ex
vivo
human
tissu
model
endometri
cervic
sever
day
well
provid
partial
signific
protect
hiv
challeng
h
posttransfect
moreov
mild
signific
silenc
sever
day
observ
reproduct
tract
balbc
mice
aqueou
dispers
murin
sirna
target
instil
directli
uteru
boyapalleet
al
propos
interest
system
base
chitosanlipofectamin
np
mean
hydrodynam
diamet
nm
deliveri
plasmid
dna
code
variou
sirna
target
viral
tat
rev
gag
host
factor
antiinflammatori
cream
unspecifi
composit
use
vehicl
np
administr
pilot
studi
cream
contain
plasmid
sirna
cocktail
administ
intravagin
three
rhesu
macaqu
day
well
day
viral
challeng
shiv
complet
block
infect
observ
although
plasmat
viral
load
treat
anim
significantli
lower
receiv
cream
also
studi
rabbit
demonstr
safeti
cream
contain
np
despit
fact
report
find
previou
studi
may
consid
borderlin
abil
propos
nanosystem
prevent
viral
transmiss
seem
support
relev
nanotechnolog
sirnabas
microbicid
develop
still
substanti
work
requir
optim
oligonucleotid
vagin
deliveri
prevent
hiv
transmiss
microand
nanofib
attract
substanti
attent
biomed
field
multipl
potenti
applic
typic
compris
stringlik
system
extend
least
sever
centimet
present
crosssect
diamet
nanoor
micromet
rang
electrospun
polymer
fiber
particular
found
use
novel
versatil
drug
deliveri
platform
applic
develop
vagin
microbicid
activ
explor
featur
may
consid
use
think
prevent
hiv
transmiss
includ
larg
surfac
area
fiber
allow
enhanc
interact
fiber
surfac
outer
environ
compon
includ
hiv
capac
form
meshlik
structur
bear
variabl
pore
size
may
restrict
transport
sperm
virus
abil
incorpor
multipl
compound
distinct
physicochem
properti
alongsid
interest
studi
huang
et
al
phsensit
capbas
fiber
hivtrap
polystyrenebas
fiber
well
recent
report
youan
cowork
thiolat
chitosan
peo
shellthiol
hyaluron
acid
plu
poli
lactic
acid
shell
nanofib
deliveri
tenofovir
research
effort
undertaken
woodrow
cowork
univers
washington
latter
research
abl
produc
multipl
nanofib
formul
electrospin
use
variou
matrixform
materi
composit
eg
peo
polyvinylpyrrolidon
plga
polyllactid
pcl
incorpor
variabl
dose
differ
drug
last
includ
compound
antivir
effect
eg
zidovudin
tenofovir
maraviroc
raltegravir
even
differ
pharmacolog
activ
inde
combin
incorpor
antiherpet
acyclovir
contracept
levonorgestrel
spermicid
glycerol
monolaur
compound
make
nanofib
interest
deliveri
platform
design
multipurpos
prevent
technolog
mpt
superimpos
interlac
nanofib
may
allow
obtain
mesh
small
pore
diamet
restrict
pathogen
sperm
mobil
thu
provid
addit
antiinfect
contracept
mechan
respect
develop
mpt
product
consid
highli
relev
apart
prevent
hiv
transmiss
also
use
avert
sexual
transmit
infect
andor
provid
addit
contracept
option
women
modif
composit
electrospin
process
shown
easili
undertaken
effect
modul
properti
fiber
diamet
degradationdissolut
surfac
morpholog
microstructur
drug
load
crystallin
result
fabric
ie
thick
tensil
strength
young
modul
ultim
affect
drug
releas
profil
bulk
fabric
shown
readili
shape
tamponlik
shape
may
allow
conveni
vagin
administr
also
success
costeffect
scaleup
product
process
typic
use
laboratori
demonstr
poli
vinyl
alcohol
pva
base
nanofib
nm
mean
crosssect
diamet
tenofovirload
valu
ww
abil
produc
nanofib
industri
scale
seem
critic
consid
effect
afford
microbicid
high
market
demand
gener
nanofib
produc
woodrow
cowork
appear
present
favor
vitro
safeti
profil
observ
toxic
seem
mostli
determin
use
materi
activ
molecul
consist
vivo
data
still
miss
carrier
preliminari
experi
mice
evidenc
polyllactidepeo
nanofib
around
nm
diamet
provid
rapid
extens
coat
vagin
mucosa
assess
use
vivo
imag
system
develop
microbicid
nanofib
eagerli
await
use
practic
import
develop
platform
microbicid
nanosystem
allow
adequ
stabil
administr
perform
loco
eg
good
distribut
retent
throughout
mucosa
guarante
safeti
potenti
effect
platform
may
dosag
form
commonli
use
vagin
rectal
administr
imposs
establish
one
dosag
form
preferenti
end
user
perspect
men
women
product
accept
wide
variabl
among
differ
sociodemograph
socioeconom
background
henc
consid
multipl
platform
develop
nanotechnologybas
microbicid
product
appear
interest
follow
footstep
earli
microbicid
gel
frequent
propos
dosag
form
incorpor
microbicid
nanosystem
either
inher
activ
eg
vivagel
act
drug
carrier
last
case
differ
exampl
describ
literatur
particularli
poloxamerbas
thermosensit
gel
vagin
administr
describ
section
approach
achiev
easytoadminist
liquid
promot
retent
solgel
transit
occur
due
increas
temperatur
moreov
poloxamerbas
gel
appear
gener
safe
interfer
significantli
antiretrovir
activ
gel
howev
may
present
sever
limit
consid
develop
nanomicrobicid
gener
issu
concern
vagin
leakag
administr
due
typic
aqueou
natur
stabil
issu
may
also
aris
particularli
relat
prematur
releas
antiretrovir
drug
nanocarri
system
moreov
gel
requir
use
applic
increas
cost
name
singl
use
prefil
applic
consid
portabl
somewhat
limit
due
bulki
gel
tube
applic
overcom
problem
polymer
film
propos
platform
vagin
administr
antiretrovir
drug
nanocarri
vagin
film
long
use
drug
deliveri
gener
regard
accept
women
system
usual
compris
thin
flexibl
smooth
sheet
variabl
color
transpar
well
shape
mainli
squar
rectangular
area
cm
film
matrix
typic
compris
hydrophil
polym
eg
pva
cellulos
deriv
carrageenan
plastic
eg
glycerin
peo
well
variou
option
excipi
eg
stabil
preserv
disintegr
gener
film
design
dissolv
disintegr
rapidli
releas
payload
studi
detail
np
film
potenti
microbicid
product
describ
tabl
exampl
group
demonstr
versatil
potenti
use
npsinfilm
system
deliv
combin
hydrophob
efavirenz
hydrophil
tenofovir
antiretrovir
drug
efavirenzload
plga
np
tenofovir
incorpor
polym
matrix
manufactur
solvent
cast
obtain
film
fig
character
physicochem
characterist
relev
vagin
administr
organolept
featur
drug
releas
mechan
properti
disintegr
simul
vagin
fluid
osmol
ph
upon
disintegr
ex
vivo
adhes
pig
vagin
mucosa
found
suitabl
anim
vivo
test
film
increas
vagin
retent
np
mous
model
compar
administr
pb
suspens
furthermor
np
found
deepli
penetr
mucosa
reach
stroma
pk
efavirenz
vagin
tissu
lavag
improv
drug
associ
np
rel
bioavail
tissu
lavag
increas
roughli
time
respect
compar
film
contain
free
efavirenz
ie
directli
dispers
film
matrix
without
incorpor
np
drug
assay
perform
use
valid
liquid
chromatographytandem
mass
spectrometri
method
final
np
film
shown
safe
assess
histolog
analysi
measur
proinflammatori
mediat
kc
vagin
lavag
upon
daili
vagin
administr
day
data
seem
support
tenofovir
efavirenzload
np
film
promis
candid
microbicid
product
topic
administr
antiretrovir
drugbas
microbicid
may
interest
prevent
approach
circumv
hivaid
epidem
nanotechnolog
provid
interest
tool
aid
vagin
andor
rectal
deliveri
promis
antihiv
drug
exampl
case
studi
describ
subchapt
provid
consist
evid
nanocarri
system
contribut
develop
novel
microbicid
product
particular
polymer
nanosystem
seem
particularli
suitabl
deliv
promis
antiretrovir
drug
still
import
work
requir
regard
optim
platform
administr
nanocarri
longterm
safeti
nanomicrobicid
scaleup
feasibl
industri
product
afford
product
final
substanti
research
effort
nanotechnologybas
approach
develop
rectal
microbicid
eagerli
requir
despit
progress
modern
medicin
infect
continu
repres
one
greatest
challeng
face
human
type
infect
broadli
divid
two
main
categori
accord
locat
patient
time
infect
develop
communityacquir
nosocomi
hospitalacquir
infect
nosocomi
infect
occur
worldwid
affect
develop
resourcepoor
countri
mostli
relat
infect
surgic
wound
well
urinari
lower
respiratori
tract
infect
acquir
healthcar
set
among
major
caus
death
increas
morbid
among
hospit
patient
lead
consequ
remark
increas
healthcar
cost
europ
estim
cost
billion
per
year
includ
direct
cost
reflect
million
extra
day
hospit
stay
european
centr
diseas
prevent
control
ecdc
estim
nosocomi
infect
contribut
death
europ
averag
hospit
patient
nosocomi
infect
europ
million
individu
annual
almost
worldwid
increas
length
stay
infect
patient
greatest
contributor
cost
one
studi
show
overal
increas
durat
hospit
patient
surgic
wound
infect
day
rang
day
gynecolog
day
gener
surgeri
day
orthoped
surgeri
prolong
stay
increas
direct
cost
patient
payer
also
indirect
cost
due
lost
work
advanc
age
greater
preval
chronic
diseas
among
admit
patient
well
increas
use
diagnost
therapeut
procedur
affect
host
defens
provid
continu
pressur
nosocomi
infect
futur
increas
use
drug
need
isol
use
addit
laboratori
diagnost
studi
also
contribut
cost
addit
rapid
longrang
human
mobil
respons
fast
geograph
spread
infecti
diseas
make
fight
infect
tackl
global
nowaday
mobil
traffic
reach
complex
volum
unpreced
degre
million
peopl
travel
billion
mile
million
intern
flight
week
hundr
million
peopl
u
b
c
h
p
e
r
surfaceenhanc
raman
scatter
ser
method
diagnosi
infecti
diseas
subchapt
commut
complex
web
highway
railroad
oper
maximum
capac
despit
increas
connect
abil
visit
virtual
everi
place
planet
matter
day
magnitud
intens
modern
human
traffic
made
human
societi
suscept
threat
intim
connect
human
travel
notabl
although
communityacquir
nosocomi
infect
due
mani
agent
infect
ascrib
around
microorgan
fig
time
effect
antimicrobi
therapi
initi
known
singl
strongest
predictor
outcom
even
delay
hour
administr
increas
risk
death
besid
obviou
econom
benefit
develop
fast
accur
inexpens
diagnost
method
thu
appear
major
goal
allevi
human
pain
convent
microbi
type
method
reliabl
suffer
inher
timeconsum
complex
among
method
common
one
remain
cultur
microorgan
differ
media
isol
speci
identifi
natur
fig
sequenti
cultur
avoid
implement
mass
spectrometri
ms
techniqu
identif
isol
pure
coloni
fig
method
includ
identif
ms
requir
time
agent
grow
h
hand
immunolog
test
identifi
microorgan
also
popular
immunolog
techniqu
enzymelink
immun
sorbent
assay
elisa
fig
fluoresc
immun
assay
fia
radioimmunoassay
ria
offer
faster
result
consid
multiplex
assay
requir
consider
amount
sampl
expens
analyt
kit
automat
system
increment
portabl
new
fluoresc
immun
assaylik
techniqu
known
later
flow
immunochromatographi
recent
infect
antimicrobi
use
epp
introduct
develop
fig
method
simpl
chemic
store
certain
time
offer
result
easili
interpret
nake
eye
ie
requir
extens
train
personnel
howev
reactiv
strip
necessari
identifi
singl
given
agent
singl
given
sampl
furthermor
method
suffer
poor
sensit
thu
accumul
microorgan
sampl
necessari
step
allow
posit
detect
target
altern
lab
introduc
polymeras
chain
reaction
pcr
identifi
microorgan
profil
genet
code
fig
techniqu
quantit
semimultiplex
also
labori
slow
expens
analysi
sampl
overal
conclud
current
method
detect
microorgan
flaw
problem
relat
sensit
select
speed
price
technolog
restrict
scenario
surfaceenhanc
raman
scatter
ser
spectroscopi
offer
except
opportun
develop
new
sens
devic
amen
implement
quantit
multiplex
analysi
real
time
applic
nanostructur
materi
toward
develop
novel
detect
techniqu
improv
sensit
andor
simplifi
faster
applic
rapidli
becom
appeal
altern
technolog
among
ser
power
analyt
techniqu
alreadi
proven
particularli
effect
environment
detect
monitor
applic
essenti
ser
describ
raman
scatter
amplifi
presenc
plasmon
structur
close
vicin
target
analyt
case
main
caus
excit
vibrat
level
molecul
collect
oscil
conduct
electron
metal
upon
excit
appropri
light
gener
ultrastrong
electromagnet
nearfield
proxim
nanostructur
surfac
known
local
surfac
plasmon
reson
raman
scatter
ser
provid
complex
spectral
pattern
contain
composit
structur
characterist
molecul
studi
ser
raman
also
character
extrem
experiment
flexibl
raman
measur
carri
wide
spectral
rang
insensit
air
water
requir
sampl
prepar
recent
spectacular
advanc
nanofabr
techniqu
fuell
develop
larg
varieti
ration
design
ser
substrat
optim
uniform
reproduc
respons
success
translat
outstand
analyt
potenti
ser
reliabl
wide
accept
commerci
viabl
sens
applic
depend
local
surfac
plasmon
reson
paramet
size
shape
composit
surround
medium
provid
multipl
possibl
tune
optic
respons
thu
optim
ser
perform
plasmon
nanostructur
specif
applic
conjunct
control
signal
amplif
provid
optic
enhanc
key
step
practic
implement
sens
applic
includ
ser
appropri
chemic
function
bare
metal
surfac
step
necessari
impart
requir
select
andor
sensit
toward
target
analyt
especi
complex
medium
two
design
approach
commonli
use
devis
plasmon
nanostructur
ser
sens
platform
direct
ser
encod
particl
direct
ser
detect
achiev
directli
acquir
ser
spectrum
analyt
howev
perform
direct
ser
sever
speci
besid
target
molecul
detect
simultan
thu
hamper
applic
strategi
complex
analyt
matrix
involv
biolog
environment
applic
fact
number
target
background
speci
high
overlap
vibrat
mode
differ
molecul
like
henc
make
interpret
overal
vibrat
spectrum
extrem
difficult
nearli
imposs
hand
sersencod
particl
typic
prepar
use
effici
plasmon
substrat
label
ser
molecul
protect
extern
inert
layer
function
appropri
select
chemoreceptor
antibodi
ab
aptam
case
identif
quantif
analyt
indirectli
correl
presenc
intens
specif
ser
label
critic
aspect
implement
sersbas
sens
strategi
microorgan
detect
reli
prepar
appropri
plasmon
materi
gener
format
function
plasmon
materi
dictat
select
strategi
ie
either
direct
ser
use
encod
nanoparticl
task
find
univers
ser
substrat
trivial
may
even
right
approach
implement
ser
analyt
tool
practic
quantit
analyt
applic
ser
must
fulfil
typic
requir
analyt
techniqu
reproduc
result
linear
respons
standard
molecular
select
clear
methodolog
sampl
prepar
unfortun
requir
easili
met
case
ser
experi
chemic
electron
effect
must
care
control
bring
ser
close
possibl
basic
analyt
requir
ser
maxim
mainli
control
two
main
factor
care
design
optic
substrat
appropri
function
regard
optic
substrat
ser
mainli
obtain
nanostructur
thin
film
colloid
nanoparticl
colloid
nanoparticl
advantag
mani
reason
versatil
eas
synthesi
high
degre
control
composit
shape
size
make
far
commonli
use
substrat
ser
care
control
three
key
factor
composit
size
shape
optic
plasmon
properti
tune
maxim
ser
enhanc
composit
metal
nanoparticl
deepli
affect
intens
ser
signal
respect
import
ser
platform
far
made
silver
gold
research
use
materi
cu
pd
pt
rh
cute
si
etc
still
margin
gener
state
silver
much
effici
optic
materi
gold
give
rise
ser
signal
order
magnitud
higher
gold
silver
scatter
contribut
larger
gold
addit
silver
excit
radiat
rang
uv
ir
gold
restrict
red
ir
spectrum
owe
damp
interband
transit
consequ
silver
nanoparticl
prefer
deal
practic
applic
howev
worth
note
gold
nanoparticl
permit
better
control
particl
size
shape
also
significantli
stabl
biocompat
current
mani
method
avail
obtain
colloid
high
ser
activ
topic
continu
boom
research
field
within
limit
wet
chemistri
colloid
method
divid
varieti
process
includ
chemic
reduct
laser
ablat
photoreduct
first
one
commonli
use
chemic
reduct
usual
compris
metal
salt
precursor
reduc
chemic
agent
produc
colloid
dispers
contain
particl
differ
size
variabl
shape
regard
synthesi
silver
nanoparticl
tune
size
shape
properti
much
difficult
achiev
case
gold
due
higher
reactiv
silver
limit
extent
control
exert
select
growth
differ
crystal
facet
howev
mani
synthet
process
describ
obtain
differ
size
shape
nanoparticl
includ
seedmedi
polyol
biolog
hydro
solvotherm
galvan
replac
photochem
electrochem
templatemedi
synthesi
give
rise
highli
monodispers
colloid
shape
size
among
method
seedmedi
growth
process
wide
use
deal
shapecontrol
nanoparticl
synthesi
protocol
includ
twostep
process
first
step
consist
gener
small
spheric
particl
second
step
particl
grow
anisotrop
differ
direct
due
reduct
metal
salt
surfac
initi
seed
nanoparticl
presenc
preform
seed
highli
advantag
particl
size
distribut
becom
significantli
narrow
control
experiment
variabl
concentr
metal
salt
reduc
agent
growth
speed
temperatur
cap
agent
chosen
solvent
provid
broad
rang
differ
size
shape
nanoparticl
fig
besid
simplic
synthet
method
asprepar
metal
nanoparticl
present
remark
advantag
deal
diagnost
system
biofluid
permit
direct
ser
analysi
within
analyt
natur
solut
medium
present
larg
surfac
area
good
dispers
liquid
allow
close
despit
advantag
mention
earlier
bare
plasmon
nanoparticl
usual
enough
appropri
recognit
complex
analyt
microorgan
direct
ser
spectra
microorgan
usual
show
common
spectral
pattern
especi
studi
close
relat
speci
addit
goal
method
determin
microorgan
directli
biolog
matrix
chemic
speci
present
overlap
microorgan
ser
spectra
make
interpret
result
imposs
thu
altern
ser
use
label
method
similar
way
fluorophor
use
immunolog
bioassay
although
fluoresc
power
conveni
lack
featur
obtain
spectra
usual
compos
one
broad
featur
limit
number
analyt
recogn
certainti
thu
use
ser
encod
altern
rapidli
gain
relev
due
unpreced
detect
limit
dramat
decreas
detect
time
also
owe
practic
unlimit
number
barcod
use
simultan
detect
fabric
characterist
materi
size
biocompat
other
desir
sersencod
particl
strongli
depend
specif
applic
howev
share
common
requir
presenc
optic
enhanc
ie
plasmon
nanomateri
addit
ser
code
protect
silica
polym
layer
prevent
leach
ser
report
provid
suitabl
surfac
biofunction
colloid
stabil
fig
first
report
work
use
sersencod
particl
multiplex
determin
reli
either
addit
ser
tag
directli
onto
plasmon
particl
precoupl
tag
biomolecular
interfac
nowaday
prepar
sersencod
particl
becom
exot
simplest
way
produc
sersencod
nanoparticl
compris
ser
codif
singl
spheric
plasmon
colloid
encapsul
within
silica
polym
shell
hand
silica
coat
nanoparticl
also
matur
technolog
thu
key
step
codif
singl
nanoparticl
reli
incorpor
raman
label
give
rise
signal
strong
possibl
without
compromis
colloid
stabil
format
protect
shell
around
singl
colloid
particl
inhibit
plasmon
coupl
turn
gener
hot
spot
specif
gap
particl
electromagnet
field
extrem
high
due
coupl
plasmon
reson
even
though
recent
demonstr
heterogen
distribut
plasmon
mode
within
anisotrop
particl
lead
develop
highli
activ
nanoparticl
nanostar
lace
nanoshel
fig
still
popular
approach
fabric
nanometers
sersencod
particl
use
nanoparticl
aggreg
plasmon
core
particl
aggreg
easili
promot
chang
solvent
increas
ionic
strength
suspens
spontan
due
adsorpt
raman
label
notwithstand
uncontrol
aggreg
process
usual
undesir
lead
random
distribut
hot
spot
subsequ
signal
heterogen
cluster
cluster
thu
sever
approach
develop
toward
control
aggreg
one
oldest
probabl
success
approach
compris
socal
composit
organicinorgan
nanoparticl
coin
coin
approach
consist
control
labelinduc
aggreg
silver
particl
extern
shell
bovin
serum
albumin
bsa
spontan
retain
onto
coin
protect
code
also
allow
function
biomolecul
protein
antibodi
strategi
gener
aggreg
encod
particl
reli
induct
aggreg
increas
ionic
strength
follow
silica
coat
silver
gold
colloid
fact
particl
recent
demonstr
give
rise
suffici
intens
signal
enabl
individu
identif
raman
flow
cytomet
nevertheless
method
still
yield
uncontrol
aggreg
ensu
fluctuat
ser
intens
reason
increas
activ
observ
develop
control
method
fabric
ser
activ
dimer
includ
sphere
cage
pyramid
even
rod
fig
common
approach
ser
analysi
bacteria
reli
acquisit
intrins
ser
spectra
microorgan
place
direct
contact
ser
substrat
tradit
achiev
simpli
dri
mixtur
unfunction
nake
silver
nanoparticl
highli
concentr
bacteria
onto
appropri
raman
spectroscopi
substrat
prior
spectral
acquisit
fig
larg
number
ser
spectra
collect
differ
point
improv
statist
reliabl
reproduc
final
bacteri
fingerprint
fig
chemometr
final
appli
posit
identif
discrimin
bacteria
fig
scenario
ser
spectra
sole
result
contribut
compon
bacteri
membran
nonetheless
final
spectral
profil
shown
extrem
sensit
sever
experiment
factor
colloid
properti
sampl
prepar
particular
rather
nonhomogen
distribut
nanoparticl
onto
bacteri
wall
significantli
limit
spectral
reproduc
hamper
quantit
estim
target
concentr
sever
new
approach
develop
solv
problem
reduct
bacteri
concentr
requir
achiev
detect
signal
instanc
magneticplasmon
coreshel
nanoparticl
use
place
tradit
colloid
enabl
high
concentr
bacteria
appli
extern
point
magnet
field
result
larg
number
microorgan
nanoparticl
effect
condens
highli
compact
dot
fig
hand
szymborski
et
al
combin
period
structur
nanos
fiber
nanostructur
gold
layer
use
dualeffici
ser
filter
immobil
bacteria
solut
blood
urin
water
milk
fig
addit
mechan
forc
strategi
exploit
biochem
interact
develop
purpos
paradigmat
exampl
repres
work
wang
cowork
sersact
silver
nanoparticl
array
coat
vancomycin
van
antibiot
use
treat
number
bacteri
infect
profit
high
bind
affin
bacteria
toward
van
increas
bacteria
captur
biofluid
saliva
phlegm
blood
achiev
without
introduct
signific
spectral
interfer
fig
vancoat
ser
substrat
act
bacteriacaptur
tool
effici
sens
platform
identif
ser
fingerprint
target
bacteria
author
report
concentr
enterococcu
present
ml
water
cfuml
ad
onto
microscop
vancoat
area
diamet
microscop
local
help
reduc
labori
procedur
requir
locat
bacteria
substrat
therefor
facilit
subsequ
sens
ser
despit
improv
regard
sampl
manipul
concentr
tradit
approach
direct
ser
analysi
bacteria
dri
solid
substrat
major
issu
term
spectral
fluctuat
extrem
long
measur
time
acquir
statist
reliabl
dataset
lack
quantit
respons
limit
potenti
address
combin
ser
microfluid
recent
advanc
microfabr
led
develop
novel
microflow
system
bioparticl
separ
analysi
implement
microfluid
biosensor
technolog
provid
abil
manag
integr
chemic
biolog
compon
singl
platform
offer
opportun
develop
portabl
autonom
dispos
devic
capabl
perform
realtim
detect
unpreced
accuraci
simultan
analysi
differ
analyt
singl
devic
microsystem
alreadi
revolution
way
scienc
led
develop
number
ultrasensit
bioanalyt
devic
capabl
analyz
complex
biolog
sampl
popp
cowork
provid
first
exampl
flowthrough
ser
measur
bacteri
sampl
microfluid
devic
fig
approach
drastic
reduc
acquisit
time
improv
spectral
reproduc
analysi
sampl
suspens
initi
author
demonstr
effici
ser
microfluid
devic
classif
nine
differ
precultiv
escherichia
coli
strain
buffer
solut
ca
cellsml
subsequ
six
differ
speci
precultiv
mycobacteria
buffer
solut
concentr
rang
ca
cellsml
success
identifi
latter
work
beadbeat
modul
disrupt
bacteri
cell
combin
microfluid
devic
fig
lead
autom
close
system
sampl
prepar
measur
disrupt
bacteri
membran
allow
colloid
silver
nanoparticl
interact
cell
compon
rather
bacteri
wall
alon
result
richer
spectral
inform
avail
ser
spectra
thu
improv
overal
discrimin
capabl
via
chemometr
method
ultim
goal
bacteri
identif
complet
bypass
cultiv
step
concentr
procedur
implement
ser
microfluid
biosensor
mostli
base
microfluid
dielectrophoresi
dep
dep
nonuniform
electr
field
exert
dielectr
particl
includ
cell
microorgan
control
locat
cheng
et
al
combin
shortrang
dep
longrang
ac
electroosmosi
flow
rapidli
select
concentr
pathogen
dilut
human
blood
sampl
stagnat
area
sersact
roughen
electrod
high
densiti
bacteria
aggreg
measur
spot
achiev
intens
ser
fingerprint
staphylococcu
aureu
e
coli
pseudomona
aeruginosa
spike
blood
ca
cfuml
typic
dilut
human
whole
blood
sampl
spike
pathogen
dilut
necessari
avoid
blood
cell
coagul
drop
onto
chip
subject
ac
excit
min
ca
captur
effici
onto
stagnat
area
achiev
investig
ser
min
microfluid
dep
devic
also
integr
ser
use
encod
nanoparticl
detect
bacteria
madiyar
et
al
captur
concentr
e
coli
cell
coat
ser
tag
nanoelectrod
array
place
bottom
microfluid
chip
fig
ser
signal
success
measur
dep
captur
singlebacterium
sensit
quantit
respons
cfuml
rang
buffer
solut
sersencod
nanoparticl
consist
iron
oxidegold
coreshel
nanoparticl
initi
coat
thiolat
peg
infus
raman
report
final
conjug
select
ab
typic
bacteria
antibodyconjug
sersencod
nanoparticl
solut
mix
togeth
incub
overnight
sever
centrifugationwash
cycl
appli
remov
excess
unbound
particl
integr
ser
microfluid
devic
sersencod
nanoparticl
analysi
bacteria
detect
also
success
perform
complex
media
spike
cfuml
e
coli
cell
lin
et
al
exploit
dep
microfluid
devic
trap
individu
microorgan
defin
locat
space
situ
investig
confoc
microraman
system
cluster
gold
nanoparticl
aggreg
presenc
dye
molecul
silicaco
bioconjug
ab
use
sersencod
nanoparticl
buffer
suspens
two
bacteria
salmonella
enterica
serotyp
choleraesui
neisseria
lactamica
mix
sersencod
particl
incub
h
room
temperatur
subject
multipl
centrifugationwash
cycl
elimin
unbound
nanoparticl
prior
depraman
analysi
practic
detect
limit
measur
time
estim
cfuml
total
assay
time
includ
sampl
pretreat
less
h
quantit
respons
report
aim
improv
detect
specif
signal
enhanc
reduc
miss
bind
wang
et
al
recent
develop
biosensor
use
threeepitop
detect
scheme
avoid
antibodyantigen
bind
failur
may
occur
oneepitop
setup
differ
sersencod
nanoparticl
conjug
three
monoclon
antibodi
bind
three
differ
membran
receptor
buffer
suspens
e
coli
preconcentr
via
dep
microfluid
devic
incub
mixtur
sersencod
nanoparticl
ser
analysi
perform
droplet
sampl
solut
place
goldcoat
microscop
slide
setup
ser
signal
consist
superimpos
contribut
differ
ser
tag
associ
posit
recognit
event
limit
detect
cfuml
report
unfortun
sensit
issu
address
method
small
volum
sampl
normal
relev
clinic
diagnosi
actual
investig
addit
step
record
suitabl
signal
identif
often
requir
recent
group
report
fabric
novel
microorgan
optic
detect
system
mod
fig
realtim
multiplex
pathogen
identif
quantif
singl
colonyform
unit
detect
fast
screen
larg
bodi
fluid
volum
minml
blood
requir
standard
medic
practic
analysi
biolog
sampl
previou
sens
scheme
mix
bacteriacontain
fluid
antibodyfunction
sersencod
silver
nanoparticl
induc
accumul
particl
bacteri
membran
case
howev
sersencod
particl
design
yield
upon
adhes
onto
bacteria
wall
dens
array
interparticl
gap
raman
signal
exponenti
amplifi
sever
order
magnitud
rel
dispers
particl
incub
time
optim
maxim
nanoparticl
coat
satur
point
avoid
unwant
floccul
bacteria
overload
nanoparticl
fig
scenario
sampl
directli
pump
millifluid
channel
backscatt
detect
laser
continu
monitor
liquid
stream
therefor
remov
need
timeconsum
centrifugationwash
cycl
prior
ser
analysi
fact
posit
event
associ
nanoparticleco
colonyform
unit
travers
laser
focu
gener
ser
intens
well
background
dispers
encod
nanoparticl
demonstr
bacteria
detect
success
simultan
quantifi
three
differ
type
bacteria
aureu
e
coli
streptococcu
agalactia
rate
minml
blood
serum
fig
concentr
rang
unit
ten
colonyform
unit
per
millilit
notabl
fals
identif
observ
analys
posit
event
record
blank
sampl
obtain
concentr
consist
found
use
convent
bacteri
cultur
consider
lower
standard
deviat
fig
antibodi
excel
option
accur
recognit
specif
target
howev
expens
produc
delic
handl
rather
larg
size
factor
limit
format
activ
hot
spot
last
year
new
famili
biomolecul
aptam
develop
effici
altern
antibodi
aptam
display
similar
even
larger
target
specif
provid
key
advantag
term
stabil
immunogen
facil
product
function
reduc
size
address
point
recent
extend
use
mod
onlin
ser
quantif
bacteria
differ
human
fluid
urin
blood
pleural
ascit
fluid
infect
low
concentr
aureu
use
aptamerfunction
sersencod
nanoparticl
work
extens
character
effici
differ
biofunction
sersencod
particl
demonstr
import
advantag
use
aptam
antibodi
biorecognit
element
first
aptam
exhibit
much
larger
affin
bacteria
antibodi
second
final
ser
intens
regist
aptam
nanoparticl
satur
around
larger
antibodi
explain
consid
antibodi
conjug
onto
nanoparticl
surfac
result
random
orient
fraction
attach
antibodi
experi
inactiv
bind
site
ie
paratop
convers
aptam
easili
functionalizedmodifi
without
loss
activ
conjug
nanoparticl
surfac
direct
yield
conform
suitabl
effici
interact
target
entiti
furthermor
smaller
size
aptam
reduc
interparticl
gap
bacteri
surfac
lead
overal
increas
electromagnet
energi
gener
hot
spot
ser
probe
label
offer
sever
advantag
optic
probe
respect
versatil
sensit
select
biocompat
futur
challeng
includ
develop
multifunct
ser
probe
optim
plasmon
nanostructur
basic
build
block
plasmon
structur
key
compon
ser
probe
offer
high
local
optic
field
sensit
diagnost
probe
ser
much
lower
acquisit
time
later
paramet
paramount
import
due
sampl
volum
commonli
screen
actual
medic
practic
util
progress
made
design
sersencod
particl
applic
ser
probe
revolution
bioanalysi
first
proofofprincipl
studi
promis
pave
way
enabl
multiplex
identif
quantif
microorgan
directli
biolog
matrix
unpreced
speed
low
cost
sensit
introduct
nuclear
medicin
branch
medicin
use
radiat
provid
inform
function
person
specif
tissueorgan
treat
diseas
radiolabel
nanoparticl
np
repres
new
class
agent
great
potenti
nuclear
medicin
applic
key
advantag
use
radiolabel
np
small
amount
use
obtain
inform
great
import
may
use
detect
character
diseas
deliv
relev
therapeut
monitor
therapeut
effect
well
furthermor
radiotracerbas
imag
either
use
singlephoton
emiss
comput
tomographi
spect
positron
emiss
tomographi
pet
particularli
suit
studi
pharmacokineticpharmacodynam
paramet
nanomateri
determin
optim
nanodimension
architectur
tissueorgan
regener
measur
radiat
radioact
tracer
attach
np
demonstr
highli
sensit
specif
method
allow
accur
quantif
without
limit
tissu
penetr
organ
nuclear
imag
approach
highli
suitabl
detect
offer
high
detect
sensit
high
tempor
spatial
resolut
requir
radionuclid
concentr
around
site
interest
nanoparticul
agent
typic
demonstr
pharmacokinet
behavior
differ
small
molecul
provid
flexibl
platform
integr
multipl
function
entiti
includ
target
ligand
multipl
type
contrast
materi
andor
therapeut
contrast
tradit
compound
use
radiopharmaceut
prepar
nanomateri
immens
avail
surfac
area
per
unit
volum
tunabl
optic
electron
magnet
biolog
properti
gener
tailor
meet
need
specif
applic
engin
differ
physicochem
properti
affect
vivo
biodistribut
size
shape
chemic
composit
surfac
chemic
characterist
hollow
solid
structur
effici
diagnosisradiotherapi
provid
passiv
target
base
enhanc
permeabl
retent
epr
effect
fig
andor
activ
target
incorpor
target
moieti
np
nontarget
np
accumul
tumor
tumor
vasculatur
usual
leaki
without
lymphat
drainag
activ
target
achiev
function
np
surfac
suitabl
vector
includ
peptid
antibodi
biomolecul
recogn
characterist
epitop
surfac
diseas
cell
radiolabel
antibodi
may
effect
target
even
singl
cancer
cell
circul
small
cancer
cell
cluster
therebi
enabl
specif
radiat
dose
deliveri
prevent
damag
healthi
tissu
sever
key
issu
need
address
select
applic
radionuclid
radiolabel
np
contrast
np
product
radiolabel
process
time
limit
difficult
contamin
risk
handl
radionuclid
carri
special
design
radiochem
laboratori
control
ventil
air
condit
shield
remot
handl
facil
special
equip
intend
measur
radioact
select
radionuclid
two
main
method
fabric
radionuclid
use
nuclear
reactor
use
particl
acceler
method
complementari
provid
wide
varieti
radionuclid
applic
medicin
research
fig
abil
access
radionuclid
without
use
onsit
acceler
reactor
depend
avail
generatorproduc
radionuclid
parent
radionuclid
produc
reactor
cyclotron
gener
devic
use
extract
one
radionuclid
anoth
mo
tc
gener
especi
popular
conveni
differ
halfliv
chemic
properti
mo
halflif
h
tc
halflif
h
exploit
separ
gener
procedur
repeat
mani
time
provid
nearli
continu
suppli
radionuclid
low
cost
newli
develop
gener
select
criteria
radionuclid
must
base
physic
data
radionuclid
biolog
variabl
govern
use
consider
physic
characterist
includ
physic
halflif
type
emiss
energi
radiat
daughter
product
method
product
radionuclid
puriti
biochem
aspect
includ
tissu
target
retent
radioact
organtissu
vivo
stabil
toxic
diagnost
radionuclid
gener
shortliv
radionuclid
capabl
provid
necessari
inform
biodistribut
dosimetri
limit
critic
organ
tissu
radionuclid
spect
imag
decay
emiss
highenergi
photon
pet
radionuclid
decay
emiss
positron
select
appropri
therapeut
radionuclid
emit
depend
upon
natur
extent
stage
diseas
type
particul
radiat
allow
high
ioniz
per
length
travel
therefor
fulli
deposit
within
small
rang
tissu
usual
millimet
longer
rang
beta
particl
still
permit
uniform
tumor
irradi
despit
possibl
heterogen
distribut
radioact
within
tumor
therapeut
radionuclid
also
decay
advantag
energi
intens
within
diagnost
rang
distribut
radiolabel
np
visual
physic
halflif
radionuclid
play
crucial
role
measur
desir
time
frame
radionuclid
halflif
suitabl
investig
question
pharmacokinet
profil
consid
measur
within
short
initi
time
frame
intraven
administr
shortliv
pet
radionuclid
appli
exampl
halflif
min
halflif
min
even
halflif
min
convers
halflif
short
decay
occur
radiolabel
np
target
reach
maximum
tissu
accumul
major
requir
radiolabel
procedur
label
process
significantli
alter
structur
properti
np
stabil
radiolabel
product
suffici
allow
vivo
track
radiolabel
method
select
radionuclid
np
type
optim
radioact
part
may
use
track
np
also
radiodiagnosi
radiotherapi
depend
radionuclid
composit
structur
np
two
approach
may
appli
effici
radiolabel
fig
direct
radiolabel
mostli
via
nucleophilicelectrophil
label
coordin
chemistri
indirect
radiolabel
via
chelat
complex
agent
requir
addit
synthet
step
furthermor
radionuclid
attach
whole
particl
synthes
advanc
postsynthesi
approach
entrap
np
synthesi
presynthesi
approach
conveni
effici
gentl
radiolabel
procedur
requir
met
radiolabel
method
bind
radionuclid
np
irrevers
prevent
escap
tissu
organ
care
vitro
experi
measur
stabil
radiolabel
np
mostli
serum
gener
requir
prior
vivo
studi
biodistribut
pattern
radiolabel
np
seem
crucial
affect
radiolabel
approach
gener
radiolabel
np
excret
urinari
tract
via
kidney
mostli
accumul
reticuloendotheli
tissu
liver
spleen
due
substanti
uptak
macrophag
present
organ
agglomer
size
rel
larg
rang
micromet
highest
uptak
intraven
administr
occur
lung
tc
ga
commonli
use
radionuclid
np
radiolabel
radionuclid
emit
singl
photon
detect
gamma
camera
view
organ
differ
angl
radiolabel
tc
halflif
h
account
nuclear
medicin
procedur
worldwid
attribut
ideal
physic
properti
halflif
allow
prolong
vivo
imag
singleenergi
emiss
kev
benefici
effect
imag
chemic
form
tc
occur
tcpertechnet
tco
chemic
reaction
necessari
reduc
oxid
state
lower
valu
stannou
chlorid
sncl
often
use
reduc
agent
direct
method
tc
label
np
base
fact
reduc
tco
react
random
group
hydroxyl
carboxyl
amino
group
present
surfac
np
direct
label
method
use
label
hydroxyapatit
nanoparticl
hapnp
well
astaxanthinload
solid
lipid
np
direct
nosetobrain
deliveri
tclabel
lipid
np
evid
imag
suggest
potenti
use
variou
neurolog
diseas
radiolabel
dendrim
method
proven
effect
label
variou
ligand
ethylendiaminen
signific
tumor
uptak
exclus
passiv
target
np
load
compound
higher
probabl
tumor
uptak
radiomet
diagnost
cu
ga
zr
therapeut
lu
best
attach
np
via
chelat
indirect
chelatormedi
tclabel
np
appli
varieti
np
structur
helbok
et
al
perform
effici
radiolabel
pegyl
cholesterol
liposom
micel
via
acycl
diethylenetriaminepentaacet
acid
dtpa
chelat
also
poli
ethylen
glycol
peg
liposom
label
rel
easili
stabli
tc
liposom
synthesi
use
procedur
includ
conjug
tc
hexamethyl
propyleneamin
hmpao
hydrazino
nicotinamid
hynic
follow
encapsul
liposom
hynicbas
method
provid
tclabel
liposom
high
label
yield
improv
vitro
vivo
characterist
compar
liposom
label
via
tchmpao
chitosan
ch
hydrogel
np
load
vascular
endotheli
growth
factor
potent
angiogen
factor
effici
label
tc
via
dtpa
chelat
quantit
imag
tcch
np
demonstr
valuabl
strategi
combin
angiogen
therapi
custom
treatment
myocardi
ischemia
mercapto
acetyl
triglycin
appli
facilit
radiolabel
morpholino
acid
dmsa
also
suitabl
ligand
form
complex
compound
tc
ho
lu
dmsa
enabl
bident
bind
via
two
sulfur
atom
silver
nanoclust
fig
addit
radiolabel
possibl
via
bind
radiomet
dmsa
chelat
system
possibl
appli
theranost
approach
substitut
diagnost
radionuclid
therapeut
one
wherea
chelat
nanodimension
structur
remain
due
similar
chemic
properti
tc
label
procedur
base
similar
complex
chemistri
two
radionuclid
vector
studi
indirect
np
tclabel
may
includ
investig
novel
ligand
diamino
dioxim
ligand
form
neutral
lipophil
complex
tc
specifi
ligand
chemic
similar
pass
easili
intact
bloodbrain
barrier
accordingli
high
potenti
cerebr
perfus
imag
iron
oxid
nanoparticl
ionp
may
label
varieti
diagnost
therapeut
radionuclid
via
direct
indirect
chelatorbas
radiolabel
techniqu
tclabel
aminosilaneco
ionp
may
promis
candid
guid
cancer
diagnosi
magnet
hyperthermia
therapi
target
enabl
via
conjug
new
peptidebas
argglyasp
rgd
deriv
high
affin
select
integrin
receptor
present
sever
tumor
specif
charact
tcnpsrgd
confirm
receptor
block
studi
coadministr
excess
amount
nativ
peptid
block
experiment
induc
tumor
overexpress
receptor
result
significantli
reduc
uptak
tcnpsrgd
indic
specif
charact
target
ionp
fig
readili
avail
radiomet
wide
use
clinic
practic
diagnosi
sever
method
radiolabel
np
describ
literatur
involv
conjug
chelat
coupl
np
achiev
chelat
molecul
dtpa
acid
dota
conjug
polym
case
indtpapegbpcl
micel
peg
artifici
biocompat
hydrophil
polym
wide
appli
np
coat
radiotrac
method
use
prove
possibl
use
peg
deriv
tumorimag
carrier
label
via
dtpa
vivo
biodistribut
studi
demonstr
increas
tumor
uptak
prolong
circul
halflif
increas
molecular
weight
peg
np
degrad
radionuclid
detach
releas
np
caus
artifact
dual
radiolabel
use
differ
energi
spectra
incorpor
core
coat
may
use
gener
methodolog
wide
rang
engin
np
visual
degrad
process
np
vivo
label
core
indop
ionp
encapsul
insid
poli
lactidecoglycolid
nanoparticl
plga
np
prepar
bovin
serum
albumin
bsa
coat
label
electrophil
substitut
use
imag
reveal
differ
fate
core
coat
fraction
two
radionuclid
coloc
liver
lung
long
period
time
administr
suggest
np
stabl
organ
conjug
chelat
agent
np
could
affect
biodistribut
attach
chelat
could
alter
corona
micel
consequ
biodistribut
pharmacokinet
similarli
radionuclid
may
also
entrap
micellar
core
format
micel
without
need
chemic
modif
polymer
micel
lactosom
label
via
dota
spect
imag
radiotherapi
respect
biodistribut
studi
reveal
indotalactosom
select
accumul
tumor
site
mice
due
epr
effect
observ
antitumor
therapeut
effect
ydotalactosom
depend
dose
frequenc
amount
ga
cyclotronproduc
radiomet
use
imag
local
inflammatori
lesion
infect
get
better
insight
transport
mechan
peptideconjug
np
tumor
bombesin
peptidefunction
gold
nanoparticl
aunp
indirectli
label
ga
vivo
biolog
studi
galabel
aunp
human
prostat
tumorbear
mice
perform
case
ga
dtpa
deriv
unabl
provid
stabl
coordin
ga
aunp
therefor
ga
label
pursu
via
dotacontain
aunp
intraven
administr
receptormedi
pathway
appear
outweigh
epr
effect
intraperiton
administr
conclud
gastrinreleas
peptid
receptormedi
mechan
play
role
pancreat
uptak
isotop
iodin
extens
use
clinic
nuclear
medicin
imag
radiat
therapi
known
isotop
iodin
iar
suitabl
spect
pet
imag
halflif
use
longterm
track
imag
radiolabel
np
halflif
day
strong
due
mode
use
commonli
treat
thyroid
cancer
dualpurpos
theranost
radionuclid
exampl
pair
use
imag
follow
therapi
use
radiolabel
procedur
tradit
radiolabel
method
iodin
radioisotop
nucleophil
halogen
exchang
base
chloramin
oxid
refer
iodogen
method
direct
radioiodin
use
prosthet
group
tyrosin
residu
protein
tang
et
al
synthes
spectmagnet
reson
imag
mri
optic
trimod
probe
label
fluoresc
silicaco
ionp
use
iodogen
oxid
method
radioact
probe
use
label
mesenchym
stem
cell
quantit
track
migrat
biodistribut
ischem
rat
radiotrac
techniqu
demonstr
relev
approach
studi
biodistribut
fulleren
c
although
watersolubl
c
deriv
polyhydroxyl
fulleren
c
oh
n
success
radiolabel
differ
radiotrac
includ
ga
tc
c
similar
studi
perform
nanoc
studi
et
al
describ
first
time
effici
label
solvent
exchangeproduc
c
np
base
intercal
fulleren
crystal
colloid
prepar
fulleren
molecular
crystal
fill
tetrahydrofuran
thf
molecul
na
ion
pair
also
entrap
much
case
na
ad
c
dissolut
fig
label
particl
prepar
usual
requir
chemic
modif
hapnp
modifi
aminopropyltriethoxysilan
introduc
amino
group
surfac
hap
effect
radioiodin
label
without
modif
achiev
ad
oxid
agent
chloramin
situ
format
hap
result
reproduc
high
label
yield
ilabel
hap
pet
recent
develop
medicin
use
radionuclid
produc
cyclotron
cyclotron
type
particl
acceler
charg
particl
acceler
outward
center
along
spiral
path
limit
widespread
use
pet
aris
high
cost
cyclotron
need
produc
shortliv
radionuclid
pet
scan
need
special
adapt
onsit
chemic
synthesi
apparatu
radiolabel
pet
imag
facil
close
proxim
cyclotron
due
short
halflif
positronemit
radionuclid
furthermor
liposom
np
product
multipl
step
requir
much
longer
process
relat
halfliv
commonli
use
positron
emitt
nuclei
thu
label
method
compon
liposom
preformul
drug
substitut
shortliv
positronemit
radionuclid
impract
urakami
et
al
develop
rapid
effici
label
method
lipid
np
via
f
without
chang
physiolog
properti
dynam
pet
scan
show
liposomeencapsul
hemoglobin
deliv
oxygen
even
ischem
region
peripheri
toward
core
ischemia
recent
year
use
pet
isotop
rel
long
halflif
cu
zr
ga
increas
metal
coupl
straightforward
fashion
use
chelat
dtpa
dota
acid
nota
n
n
n
n
tetraacet
acid
teta
deriv
macrocycl
chelat
agent
origin
dota
design
lanthanid
eg
gd
use
wide
rang
radiomet
well
dota
four
carboxyl
function
side
chain
macrocyclebear
four
nitrogen
bind
cu
lead
deform
octahedr
complex
cu
ion
therebi
leav
two
acid
function
free
accordingli
one
avail
coupl
np
polym
allow
derivat
act
addit
hydrophil
group
review
stockhof
et
al
present
comprehens
studi
variou
approach
method
label
potenti
drug
deliveri
system
use
positron
emitt
cu
favor
decay
characterist
mev
mev
pet
radiotherapi
due
halflif
h
shown
effect
assess
behavior
nanomateri
vivo
prolong
time
function
pmmacorepegshel
np
dota
ligand
allow
chelat
cu
enabl
investig
biodistribut
materi
correl
molecular
weight
backbon
peg
graft
method
cu
label
via
nota
chelat
develop
case
crgdfunction
doxorubicinconjug
ionp
potenti
applic
drug
deliveri
petmri
dualmod
imag
also
applic
improv
culabel
procedur
via
novel
amineactiv
chelat
acid
aminebzdota
conjug
surfac
dextran
sulfateco
ionp
enabl
avoid
crosslink
ionp
caus
np
aggreg
obtain
higher
label
yield
addit
bind
tumorspecif
antibodi
culabel
doxorubicinload
silicabas
np
provid
increas
accumul
tumor
site
via
enhanc
permeabl
retent
effect
antibodymedi
bind
tumor
use
ga
positron
emiss
intens
rise
due
sever
identifi
properti
radionuclid
includ
superior
imag
qualiti
provid
spect
radionuclid
potenti
ondemand
product
via
gener
ge
gagener
success
ga
label
requir
chelat
agent
far
dota
nota
chelat
use
radiolabel
organ
inorgan
nanodimension
system
ga
cation
polyamidoamin
dendrim
pamam
conjug
success
bifunct
chelat
nhydroxysuccinimid
ester
dota
subsequ
radiolabel
ga
achiev
high
radiolabel
yield
stabil
howev
dotalik
macrocycl
best
ligand
ga
incorpor
ion
insid
macrocycl
caviti
lead
sever
distort
coordin
octahedra
around
ga
ion
notalik
ligand
bi
phosphon
contain
side
arm
bonetarget
group
connect
metalbind
cage
acetamid
methylphosphon
pendant
arm
notam
bp
bp
shown
highli
potent
chelat
small
ga
ion
synthet
apatit
nanocryst
demonstr
excel
abil
bind
two
pet
radionuclid
f
ga
good
vitro
stabil
na
f
use
direct
incorpor
radionuclid
crystal
lattic
label
surfac
function
accomplish
use
bp
current
radionuclid
therapi
remain
import
treatment
option
ioniz
radiat
radionuclid
kill
cell
inhibit
growth
peripheri
inaccess
center
cancer
lesion
site
damag
compris
cellular
level
especi
dna
nucleu
cell
intern
radiotherapi
reli
implant
radioact
seed
radiolabel
microparticl
np
deliv
highli
local
dose
diseas
area
due
inhomogen
distribut
radiolabel
particl
especi
within
larg
tumor
necrot
center
longrang
lower
linear
energi
transfer
greater
annihil
distanc
sever
cell
typic
mm
provid
larger
tortuou
radioact
dose
volum
lu
propos
suitabl
candid
intern
radionuclid
therapi
especi
primari
metastat
malign
augeremitt
due
short
rang
tissu
would
appropri
effect
kill
circul
cell
minim
irradi
blood
studi
conduct
radionuclid
ac
halflif
day
mostli
attach
chelat
highenergi
optim
nuclear
physic
characterist
halflif
h
e
max
mev
radionuclid
therapi
affect
tumor
cell
maximum
depth
mm
soft
tissu
describ
cross
fire
effect
occur
due
long
path
cross
multipl
individu
cell
decreas
need
target
cancer
cell
radiopharmaceut
radiolabel
np
ysilicatecitr
colloid
resulfur
colloid
use
radiosynovectomi
encourag
result
especi
europ
method
base
local
intraarticular
inject
nanoparticul
colloid
label
suitabl
therapeut
radionuclid
diseas
joint
phagocyt
macrophag
inflam
synovi
membran
deliv
select
radiat
dose
synovium
ylabel
colloid
np
antimoni
trisulfid
colloid
sb
tin
fluorid
colloid
snfc
potenti
applic
radiosinevactomi
snfc
particl
label
addit
ycl
format
primari
particl
nucleat
particl
growth
particl
first
aggreg
final
agglomer
due
increas
temperatur
agit
age
schemat
repres
fig
particl
size
ysnfc
differ
therapeut
applic
control
manipul
condit
colloid
form
among
differ
varieti
np
propos
use
radiosynovectomi
hap
hold
consider
promis
mainli
due
excel
properti
favor
properti
hap
biocompat
eas
synthes
within
desir
particl
size
rang
high
affin
metal
ion
led
extens
studi
radiolabel
hapnp
wide
varieti
therapeut
radionuclid
includ
sm
lu
er
ho
direct
label
hapnp
demonstr
conveni
reproduc
method
facil
prepar
ylabel
hapnp
high
radiolabel
yield
radiochem
puriti
direct
label
approach
also
use
label
fe
nake
fe
np
carboxylaterich
surfac
fe
np
suitabl
label
posit
charg
therefor
label
result
high
label
yield
good
vitro
vivo
stabil
due
signific
uptak
yfe
np
liver
low
uptak
tissu
magnetit
np
label
could
suitabl
use
combin
radiotherapyhyperthermia
cancer
treatment
magnet
np
coat
protein
human
serum
albumin
hsa
also
effect
label
direct
approach
without
surfac
chemic
modif
indirect
label
np
possibl
via
differ
ligand
acid
dpd
fig
dmsa
capabl
form
stabl
complex
lu
halflif
day
ideal
radionuclid
theranosi
particul
emiss
auger
electron
effect
therapi
emit
sever
accompani
kev
kev
use
diagnost
evalu
dosimetri
advantag
long
halflif
lu
util
map
pharmacokinet
potenti
agent
radiosynovectomi
knee
joint
therapi
hepatocellular
carcinoma
sever
studi
conduct
lulabel
aunp
imag
therapi
tumorbear
mice
aunp
modifi
peg
chain
link
dota
made
complex
compound
lu
gold
nanose
inject
intratumor
highli
effect
inhibit
growth
breast
cancer
tumor
athym
mice
caus
normal
organ
toxic
target
luaunp
conjug
rgd
peptid
show
higher
deliveri
tumor
site
nonrgd
lurgd
control
highlight
potenti
therapeut
capac
radiolabel
np
endoradiotherapi
base
previou
work
galabel
dotaconjug
bisphosphon
investig
petimag
agent
dotabas
bisphosphon
synthes
label
lu
potenti
applic
treat
metastat
bone
tumor
differ
type
np
far
label
radionuclid
inorgan
organ
metal
hybrid
one
due
good
mechan
properti
chemic
resist
biocompat
optic
electr
properti
diamond
nanoparticl
nd
repres
special
research
challeng
radiolabel
technolog
radiolabel
nd
may
suitabl
bioimag
applic
due
stabil
may
also
wider
applic
surfac
enabl
new
possibl
function
well
upload
suitabl
protein
drug
h
label
deton
nanodiamond
perform
use
tritium
microwav
plasma
fig
analysi
show
tritium
atom
strongli
bound
surfac
built
nd
core
exosom
extracellular
nanos
vesicl
cell
produc
macrophagederiv
exosomemimet
nanovesicl
label
tc
distribut
analyz
use
spectct
techniqu
vivo
result
enabl
determin
highest
accumul
tcexosomemimet
nanovesicl
liver
biodistribut
plga
np
without
encapsul
ascorb
acid
healthi
rat
examin
direct
label
tc
bind
outsid
surfac
np
investig
nanospher
exhibit
prolong
blood
circul
time
accompani
timedepend
reduct
lung
liver
spleen
quick
conveni
method
investig
pharmacolog
behavior
new
nanoparticul
system
control
system
drug
deliveri
doubl
effect
system
utmost
import
studi
releas
drug
bioresorb
polym
second
stage
resorpt
polym
investig
potenti
nonbioresorb
calcium
phosphat
filler
bone
defect
surfac
properti
plgahap
coreshel
np
load
clindamycin
chang
simul
physiolog
condit
degrad
process
could
also
investig
use
radiotrac
method
radiolabel
nanomateri
base
graphen
includ
graphen
graphen
oxid
go
reduc
graphen
oxid
rgo
graphen
quantum
dot
gqd
deriv
indic
high
potenti
imag
agent
varieti
bioimag
applic
especi
petspect
inmesopor
silica
nanoparticl
msn
prove
suitabl
track
neural
stem
cell
glioblastoma
therapi
multimod
dynam
vivo
imag
nsc
behavior
brain
import
paramet
design
control
target
success
therapi
msn
label
use
dotanhsest
amid
format
spect
confirm
abil
inmsnnsc
penetr
bloodbrain
barrier
local
tumor
cell
multimod
imag
take
advantag
two
imag
modal
provid
structur
function
molecular
inform
import
diagnosi
treatment
possibl
coupl
exampl
magnet
reson
mr
activ
np
chelat
system
therebi
enabl
vivo
track
multimod
imag
techniqu
eg
spectmri
petmri
synthes
coreshel
np
co
fe
nayf
yb
er
fe
nayf
yb
tm
stabil
bisphosphon
polyethylen
glycol
conjug
bppeg
radiolabel
f
cu
tc
fabric
particl
shown
advanc
featur
possibl
applic
trimod
imag
mri
petspect
fluoresc
imag
high
colloid
stabil
narrow
size
distribut
nm
allow
potenti
use
particl
visual
guid
surgeri
cu
label
natur
biopolymerbas
multifunct
np
success
use
cancer
multimod
petmriphotoacoust
imag
pai
imag
techniqu
dragon
fruitlik
biocag
base
apoferritin
apf
employ
fig
construct
effici
excel
biostabl
nanoplatform
apf
melanin
fe
amf
amf
suitabl
multimod
clinic
applic
radiolabel
ultrasmal
nanoparticl
usnp
core
size
nm
rang
shown
specif
featur
biomed
applic
due
potenti
usnp
interact
individu
cell
coval
attach
small
molecul
activ
molecular
target
effect
achiev
galabel
iron
oxid
success
studi
use
petmr
dualmod
imag
modal
specif
accumul
tumor
cell
znlabel
cdsecdsznsquantum
dot
znqdot
use
achiev
full
quantif
biodistribut
degrad
vivo
test
depend
attach
incorpor
radioisotop
usnp
system
far
mostli
exploit
spect
pet
imag
modal
particl
poorli
crystallin
hap
nm
coat
ch
chplga
polym
blend
shown
multifunct
characterist
bone
tissu
engin
use
situ
radiolabel
hap
hapch
hapchplga
synthes
particl
biodistribut
studi
shown
intraven
administr
normal
male
wistar
rat
hap
particl
highest
liver
accumul
min
inject
rapid
excret
bodi
without
residu
radioact
h
inject
hapch
particl
highest
accumul
liver
min
inject
consider
amount
almost
retain
h
later
hapchplga
highest
uptak
lung
min
inject
moder
retent
organ
h
later
fig
result
biodistribut
ilabel
particl
base
hap
np
indic
could
appli
organtarget
carrier
variou
drug
therapi
differ
approach
radiolabel
superparamagnet
iron
oxid
nanoparticl
spion
c
test
obtain
suitabl
system
could
use
analysi
biodistribut
concept
surfac
function
format
multipl
core
system
made
possibl
obtain
particl
hydrodynam
radiu
smaller
nm
np
function
polycarboxyl
polyamin
surfac
function
group
c
incorpor
directli
carbon
backbon
organ
molecul
concept
make
possibl
obtain
ident
surfac
chemic
function
label
nonlabel
particl
enabl
accur
analysi
prior
potenti
clinic
applic
np
carrier
crown
etherconjug
silica
sinp
radiolabel
na
load
efficaci
due
rel
long
halflif
year
radionuclid
wider
applic
biomedicin
howev
reason
na
may
repres
practic
choic
research
vivo
studi
femal
balbc
mice
old
show
nasinp
remov
organ
week
complet
month
highest
accumul
particl
record
liver
min
intraven
administr
heatinduc
metal
ionbind
reaction
enabl
radiolabel
without
modifi
surfac
structur
use
label
paramagnet
ionp
ferahem
fh
solut
compos
nonstoichiometr
fe
magnetit
core
approxim
nm
diamet
stabil
carboxymethyl
dextran
coat
total
size
nm
diamet
np
label
zr
thermal
reaction
less
min
biodistribut
zrfhnp
h
intraven
inject
mice
indic
uptak
zrfh
lymphat
system
analyz
interpret
biodistribut
variou
compon
multicompon
complex
nanosystem
concept
dual
radiolabel
np
appli
citrateco
aunp
monodispers
nm
diamet
label
c
au
use
liquid
scintil
determin
c
au
differ
biodistribut
profil
determin
au
core
citrat
surfac
coat
time
obtain
result
biodistribut
show
time
delamin
degrad
citrat
coat
np
occur
plgacoat
ionp
label
two
fig
synthesi
au
label
plga
energydiscrimin
spect
modal
use
analyz
radioisotop
independ
vivo
test
mice
balbcjrj
result
show
time
plga
surfac
coat
separ
core
detect
thyroid
gland
urin
liver
new
research
strategi
design
radiolabel
np
aim
obtain
radiolabel
multifunct
nanoobject
would
accomplish
specif
target
therapi
function
np
activ
target
target
nanoparticl
could
serv
carrier
radionuclid
radiotherapi
cancer
induc
high
mortal
cancer
cell
simultan
spare
normal
cell
minim
side
effect
hapnp
radiolabel
tc
shown
high
stabil
vivo
studi
mice
result
show
higher
affin
bone
tissu
contrast
surround
muscl
tissu
achiev
specif
target
target
nanoparticl
function
variou
molecul
anticanc
therapeut
properti
ilabel
hybrid
nanos
cyclic
rgdconjug
aunp
crgdaunp
system
test
includ
acut
apoptosi
day
posttreat
longterm
influenc
day
result
confirm
effect
target
tumor
icrgdaunp
suppress
growth
demonstr
system
base
aunp
function
epiderm
growth
factor
carrier
success
target
therapi
epiderm
growth
factor
receptorposit
cancer
target
radiotherapi
also
success
achiev
conjug
surfac
nanosystem
basi
bsa
nanocapsul
silica
monoclon
antibodi
etc
multifunct
nanoplatform
simultan
use
radiotherapi
chemotherapi
could
enabl
signific
progress
field
nanooncolog
design
lipidpolym
hybrid
nanoplatform
chemorad
fig
contain
plga
lecithin
use
suitabl
carrier
docetaxel
result
obtain
prostat
cancer
model
confirm
realiz
highli
specif
target
deliveri
drug
increas
effect
radiotherapi
time
multifunct
nanoparticul
system
hybrid
improv
properti
result
creativ
research
clear
boundari
object
diagnost
imag
therapi
biodistribut
almost
disappear
term
theranost
unifi
diagnost
therapeut
potenti
system
singl
agent
achiev
effici
specif
individu
therapi
variou
diseas
gadoliniumdop
hydroxyapatit
hapgd
nanorod
could
use
theranost
np
detect
earli
stage
osteosarcoma
carrier
radioisotop
therapi
gadolinium
endow
hap
paramagnet
properti
phosphor
gadolinium
hapgd
sampl
activ
neutron
captur
nuclear
reactor
produc
p
gd
radioisotop
multifunct
platform
base
singlewal
carbon
nanotub
swnt
coat
shell
polydopamin
pda
modifi
peg
swnt
pdapeg
label
nucleotid
potenti
allow
nuclear
imag
cancer
therapi
vivo
studi
mice
confirm
accumul
intraven
administ
iswnt
pdapeg
tumor
tissu
pda
coat
allow
easi
label
also
deliveri
due
system
abl
perform
radionuclid
therapi
well
particular
research
challeng
focus
prepar
radiolabel
np
signific
vivo
stabil
detail
analysi
chelatorfre
radiolabel
techniqu
indic
vital
import
deproton
silanol
group
zr
obtain
long
stabl
system
vivo
studi
stabil
system
indic
detach
rate
zrmsn
time
slower
zrdsio
result
obtain
pet
modal
indic
exist
mesochannel
within
msn
particl
respons
high
stabil
zrmsn
system
period
week
inject
zrmsn
accumul
liver
spleen
perceiv
bone
uptak
present
case
zrdsio
long
circul
halflif
vivo
radiolabel
np
leav
enough
time
epr
effect
success
implement
type
particl
theragnost
culabel
pegyl
reduc
graphen
oxideionp
cupegyl
rgoionp
reach
nm
size
intraven
administ
mice
ischem
hind
limb
basi
pet
doppler
imag
determin
accumul
particl
ischem
hind
limb
highest
day
lowest
day
